Publications from OUS - Department of Cardiology RG Ischemic Heart Disease

432 publications found

  1. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S et al. (2021)
    2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
    Eur J Prev Cardiol (in press)
    DOI 10.1093/eurjpc/zwab154, PubMed 34558602
  2. Täger T, Frankenstein L, Atar D, Agewall S, Frey N, Grundtvig M, Clark AL, Cleland JGF, Fröhlich H (2021)
    Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis
    Clin Res Cardiol (in press)
    DOI 10.1007/s00392-021-01913-z, PubMed 34498169
  3. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ (2021)
    Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
    Eur Heart J Cardiovasc Pharmacother (in press)
    DOI 10.1093/ehjcvp/pvab063, PubMed 34463331
  4. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S et al. (2021)
    2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
    Eur Heart J, 42 (34), 3227-3337
    DOI 10.1093/eurheartj/ehab484, PubMed 34458905
  5. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, Van Der Meer P, Lyon AR, Farmakis D, Lee G, Boriani G, Wechalekar A, Okines A, Asteggiano R (2021)
    Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases
    Eur Heart J Acute Cardiovasc Care (in press)
    DOI 10.1093/ehjacc/zuab056, PubMed 34453829
  6. Taegtmeyer H, Atar D (2021)
    Icons in Cardiology
    Cardiology (in press)
    DOI 10.1159/000519019, PubMed 34412055
  7. Awoyemi A, Mayerhofer C, Felix AS, Hov JR, Moscavitch SD, Lappegård KT, Hovland A, Halvorsen S, Halvorsen B, Gregersen I, Svardal A, Berge RK, Hansen SH, Götz A, Holm K, Aukrust P, Åkra S, Seljeflot I, Solheim S, Lorenzo A, Gullestad L, Trøseid M, Broch K (2021)
    Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial
    EBioMedicine, 70, 103511
    DOI 10.1016/j.ebiom.2021.103511, PubMed 34329947
  8. Agewall S (2021)
    Adherence to pharmacological treatment: how can we improve?
    Eur Heart J Cardiovasc Pharmacother, 7 (4), 261-262
    DOI 10.1093/ehjcvp/pvab049, PubMed 34298551
  9. Rubboli A, Atar D (2021)
    Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?
    Am J Cardiovasc Drugs
    DOI 10.1007/s40256-021-00488-4, PubMed 34254254
  10. Allahham M, Lerman A, Atar D, Birnbaum Y (2021)
    Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era
    Cardiovasc Drugs Ther
    DOI 10.1007/s10557-021-07224-9, PubMed 34245446
  11. Halvorsen S, Johnsen SP, Madsen M, Linder M, Sulo G, Ghanima W, Gislason G, Hohnloser SH, Jenkins A, Al-Khalili F, Tell GS, Ehrenstein V (2021)
    Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a scandinavian population-based cohort study
    Eur Heart J Qual Care Clin Outcomes (in press)
    DOI 10.1093/ehjqcco/qcab048, PubMed 34244745
  12. Deyab G, Reine TM, Vuong TT, Jenssen T, Hjeltnes G, Agewall S, Mikkelsen K, Førre Ø, Fagerland MW, Kolset SO, Hollan I (2021)
    Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis
    PLoS One, 16 (7), e0253247
    DOI 10.1371/journal.pone.0253247, PubMed 34242246
  13. Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Dopheide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, Agewall S (2021)
    Subgroup analyses in randomized clinical trials: Value and limitations Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy
    Eur Heart J Cardiovasc Pharmacother (in press)
    DOI 10.1093/ehjcvp/pvab048, PubMed 34180504
  14. Nguyen THP, Fagerland MW, Deyab G, Hjeltnes G, Hollan I, Feinberg MW, Eilertsen GØ, Mikkelsen K, Agewall S (2021)
    Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis
    PLoS One, 16 (6), e0253793
    DOI 10.1371/journal.pone.0253793, PubMed 34170978
  15. Rubboli A, Atar D (2021)
    The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confused
    Eur J Intern Med, 90, 125-126
    DOI 10.1016/j.ejim.2021.05.009, PubMed 34090747
  16. Ghanima W, Schultze A, Donaldson R, Brodin E, Halvorsen S, Graham S, Carroll R, Ulvestad M, Lambrelli D (2021)
    Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns
    Clin Ther (in press)
    DOI 10.1016/j.clinthera.2021.04.017, PubMed 34083030
  17. Chieffo A, Dudek D, Hassager C, Combes A, Gramegna M, Halvorsen S, Huber K, Kunadian V, Maly J, Møller JE, Pappalardo F, Tarantini G, Tavazzi G, Thiele H, Vandenbriele C, van Mieghem N, Vranckx P, Werner N, Price S (2021)
    Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices
    Eur Heart J Acute Cardiovasc Care, 10 (5), 570-583
    DOI 10.1093/ehjacc/zuab015, PubMed 34057173
  18. Chieffo A, Dudek D, Hassager C, Combes A, Gramegna M, Halvorsen S, Huber K, Kunadian V, Maly J, Møller JE, Pappalardo F, Tarantini G, Tavazzi G, Thiele H, Vandenbriele C, Van Mieghem N, Vranckx P, Werner N, Price S (2021)
    Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices
    EuroIntervention, 17 (4), e274-e286
    DOI 10.4244/EIJY21M05_01, PubMed 34057071
  19. Rønning P, Helseth E, Skaansar O, Tverdal C, Andelic N, Bhatnagar R, Melberg M, Skaga NO, Aarhus M, Halvorsen S, Helseth R (2021)
    Impact of Preinjury Antithrombotic Therapy on 30-Day Mortality in Older Patients Hospitalized With Traumatic Brain Injury (TBI)
    Front Neurol, 12, 650695
    DOI 10.3389/fneur.2021.650695, PubMed 34054695
  20. Jortveit J, Pripp AH, Halvorsen S (2021)
    Outcomes after delayed primary percutaneous coronary intervention versus pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway
    Eur Heart J Cardiovasc Pharmacother (in press)
    DOI 10.1093/ehjcvp/pvab041, PubMed 34038535
  21. Agewall S (2021)
    Different aspects of giving the optimal antiplatelet treatment
    Eur Heart J Cardiovasc Pharmacother, 7 (3), 169-170
    DOI 10.1093/ehjcvp/pvab037, PubMed 34023878
  22. Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T (2021)
    Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol
    Circulation, 143 (25), 2431-2440
    DOI 10.1161/CIRCULATIONAHA.121.054698, PubMed 33993702
  23. Rutherford OW, Jonasson C, Ghanima W, Söderdahl F, Halvorsen S (2021)
    Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
    Heart (in press)
    DOI 10.1136/heartjnl-2020-318753, PubMed 33975877
  24. Krogager ML, Kragholm K, Thomassen JQ, Søgaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall S, Niessner A, Savarese G, Kjeldsen KP, Borghi C, Tamargo J, Torp-Pedersen C (2021)
    Update on management of hypokalemia and goals for the lower potassium level in patients with cardiovascular disease: A review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
    Eur Heart J Cardiovasc Pharmacother (in press)
    DOI 10.1093/ehjcvp/pvab038, PubMed 33956964
  25. Hall TS, Atar D (2021)
    The Times They Are A-Changin´: Antithrombotic strategies in patients with acute coronary syndrome undergoing coronary stenting who have concomitant atrial fibrillation
    Eur J Intern Med, 88, 21-22
    DOI 10.1016/j.ejim.2021.04.008, PubMed 33934970
  26. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H, External reviewers:, Lip GYH, Deneke T, Dagres N, Boriani G, Chao TF, Choi EK, Hills MT, Santos IS, Lane DA et al. (2021)
    2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
    Europace (in press)
    DOI 10.1093/europace/euab065, PubMed 33895845
  27. Peterson BE, Bhatt DL, Gabriel Steg P, Oldgren J, Maeng M, Zeymer U, Halvorsen S, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Miede C, Kleine E, Ten Berg JM, Cannon CP, RE-DUAL PCI Steering Committee and Investigators (2021)
    Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial
    JACC Cardiovasc Interv, 14 (7), 768-780
    DOI 10.1016/j.jcin.2021.02.022, PubMed 33826497
  28. Pope MK, Atar D, Svilaas A, Hole T, Nielsen JD, Hintze U, Crisby M, Raatikainen P, Airaksinen KEJ, Virdone S, Pieper K, Kayani G, Le Heuzey JY, Steffel J, Stepinska J, Bassand JP, Camm AJ, GARFIELD-AF Investigators (2021)
    Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry
    Ann Med, 53 (1), 485-494
    DOI 10.1080/07853890.2021.1893897, PubMed 33818226
  29. Agewall S (2021)
    Antiplatelet treatment in coronary syndrome
    Eur Heart J Cardiovasc Pharmacother, 7 (2), 81-82
    DOI 10.1093/ehjcvp/pvab015, PubMed 33720341
  30. Blöndal M, Ainla T, Eha J, Lõiveke P, Marandi T, Saar A, Veldre G, Edfors R, Lewinter C, Jernberg T, Jortveit J, Halvorsen S, Becker D, Csanádi Z, Ferenci T, Andréka P, Jánosi A (2021)
    Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway and Sweden according to national ongoing registries
    Eur Heart J Qual Care Clin Outcomes (in press)
    DOI 10.1093/ehjqcco/qcaa098, PubMed 33710273
  31. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ (2021)
    The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
    Eur Heart J Cardiovasc Pharmacother (in press)
    DOI 10.1093/ehjcvp/pvab018, PubMed 33638977
  32. Johannessen TR, Atar D, Vallersnes OM, Larstorp ACK, Mdala I, Halvorsen S (2021)
    Comparison of a single high-sensitivity cardiac troponin T measurement with the HEART score for rapid rule-out of acute myocardial infarction in a primary care emergency setting: a cohort study
    BMJ Open, 11 (2), e046024
    DOI 10.1136/bmjopen-2020-046024, PubMed 33627355
  33. Sinning C, Ahrens I, Cariou A, Beygui F, Lamhaut L, Halvorsen S, Nikolaou N, Nolan JP, Price S, Monsieurs K, Behringer W, Cecconi M, Van Belle E, Jouven X, Hassager C, Sionis A, Qvigstad E, Huber K, De Backer D, Kunadian V, Kutyifa V, Bossaert L (2020)
    The cardiac arrest centre for the treatment of sudden cardiac arrest due to presumed cardiac cause: aims, function, and structure: position paper of the ACVC association of the ESC, EAPCI, EHRA, ERC, EUSEM, and ESICM
    Eur Heart J Acute Cardiovasc Care (in press)
    DOI 10.1093/ehjacc/zuaa024, PubMed 33620452
  34. Krychtiuk KA, Speidl WS, Giannitsis E, Gigante B, Gorog DA, Jaffe AS, Mair J, Möckel M, Mueller C, Storey RF, Vilahur G, Wojta J, Huber K, Halvorsen S, Geisler T, Morais J, Lindahl B, Thygesen K (2021)
    Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis
    Eur Heart J Acute Cardiovasc Care, 10 (3), 343-355
    DOI 10.1093/ehjacc/zuaa025, PubMed 33620437
  35. Edfors R, Jernberg T, Lewinter C, Blöndal M, Eha J, Lõiveke P, Marandi T, Ainla T, Saar A, Veldre G, Ferenci T, Andréka P, Jánosi A, Jortveit J, Halvorsen S (2021)
    Differences in characteristics, treatments and outcomes in patients with non-ST-elevation myocardial infarction -novel insights from four national European continuous real-world registries
    Eur Heart J Qual Care Clin Outcomes (in press)
    DOI 10.1093/ehjqcco/qcab013, PubMed 33605415
  36. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, Fox KAA, Gale CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M, Masoudi FA, Price S, Quinn T, Swahn E, Thiele H, Timmis A, Tubaro M, Vrints CJM, Walker D, Bueno H, ESC Scientific Document Group et al. (2021)
    2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group
    Eur Heart J Acute Cardiovasc Care, 10 (2), 224-233
    DOI 10.1093/ehjacc/zuaa037, PubMed 33550362
  37. Birnbaum Y, Nikus K, Atar D, Jneid H (2021)
    Is RBBB the new LBBB? Are we going to repeat the same mistakes?
    J Electrocardiol, 65, 34-36
    DOI 10.1016/j.jelectrocard.2020.12.010, PubMed 33477070
  38. Atar D, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, CerezoOlmos C, Underberg J, Keech A, Tokgözoğlu L, Bonaca MP (2021)
    New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
    Atherosclerosis, 319, 51-61
    DOI 10.1016/j.atherosclerosis.2020.12.013, PubMed 33476944
  39. Hijazi Z, Alexander JH, Li Z, Wojdyla DM, Mehran R, Granger CB, Parkhomenko A, Bahit MC, Windecker S, Aronson R, Berwanger O, Halvorsen S, de Waha-Thiele S, Sinnaeve P, Darius H, Storey RF, Lopes RD (2021)
    Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial
    Circulation, 143 (12), 1215-1223
    DOI 10.1161/CIRCULATIONAHA.120.051020, PubMed 33461308
  40. Camm AJ, Atar D (2021)
    Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects
    Thromb Haemost, 121 (6), 716-730
    DOI 10.1055/s-0040-1721665, PubMed 33412613
  41. Agewall S (2021)
    Atrial fibrillation in registries
    Eur Heart J Cardiovasc Pharmacother, 7 (1), 1-2
    DOI 10.1093/ehjcvp/pvaa142, PubMed 33367509
  42. De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, Lopes RD, McMurray JJV, Atar D, Bahit MC, Keltai M, López-Sendón JL, Ruzyllo W, Granger CB, Alexander JH, Wallentin L (2020)
    Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
    Eur Heart J Cardiovasc Pharmacother (in press)
    DOI 10.1093/ehjcvp/pvaa140, PubMed 33367487
  43. Sinning C, Ahrens I, Cariou A, Beygui F, Lamhaut L, Halvorsen S, Nikolaou N, Nolan JP, Price S, Monsieurs K, Behringer W, Cecconi M, Van Belle E, Jouven X, Hassager C (2020)
    The cardiac arrest centre for the treatment of sudden cardiac arrest due to presumed cardiac cause - aims, function and structure: Position paper of the Association for Acute CardioVascular Care of the European Society of Cardiology (AVCV), European Association of Percutaneous Coronary Interventions (EAPCI), European Heart Rhythm Association (EHRA), European Resuscitation Council (ERC), European Society for Emergency Medicine (EUSEM) and European Society of Intensive Care Medicine (ESICM)
    Eur Heart J Acute Cardiovasc Care, 9 (4_suppl), S193-S202
    DOI 10.1177/2048872620963492, PubMed 33327761
  44. Blichfeldt-Ærø SC, Knutsen TM, Hagen HM, Diep LM, Trondalen G, Halvorsen S (2020)
    Music therapy as an adjunct in cardiac device lead extraction procedures: A randomized controlled trial
    Appl Nurs Res, 56, 151376
    DOI 10.1016/j.apnr.2020.151376, PubMed 33280783
  45. Agewall S (2020)
    Focus on blood pressure and risk factor intervention
    Eur Heart J Cardiovasc Pharmacother, 6 (6), 339-340
    DOI 10.1093/ehjcvp/pvaa130, PubMed 33197927
  46. Maqsood MH, Alam M, Atar D, Birnbaum Y (2021)
    Efficacy of Long-Term Oral Beta-Blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis
    J Cardiovasc Pharmacol, 77 (1), 87-93
    DOI 10.1097/FJC.0000000000000922, PubMed 33136764
  47. Drexel H, Lewis BS, Rosano GMC, Saely CH, Tautermann G, Huber K, Dopheide JF, Kaski JC, Mader A, Niessner A, Savarese G, Schmidt TA, Semb A, Tamargo J, Wassmann S, Per Kjeldsen K, Agewall S, Pocock SJ (2021)
    The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials
    Eur Heart J Cardiovasc Pharmacother, 7 (5), 453-459
    DOI 10.1093/ehjcvp/pvaa126, PubMed 33135079
  48. Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG, ODYSSEY OUTCOMES Investigators (2020)
    Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
    Eur Heart J, 41 (44), 4245-4255
    DOI 10.1093/eurheartj/ehaa649, PubMed 33051646
  49. Marciniak TA, Atar D, Serebruany V (2021)
    The perils of data sharing, meta-analyses, and estimating cardiovascular risk
    Eur Heart J Cardiovasc Pharmacother, 7 (3), e55-e57
    DOI 10.1093/ehjcvp/pvaa109, PubMed 32941601
  50. El Hadidi S, Rosano G, Tamargo J, Agewall S, Drexel H, Kaski JC, Niessner A, Lewis BS, Coats AJS (2020)
    Potentially Inappropriate Prescriptions in Heart Failure with Reduced Ejection Fraction (PIP-HFrEF)
    Eur Heart J Cardiovasc Pharmacother (in press)
    DOI 10.1093/ehjcvp/pvaa108, PubMed 32941594
  51. Agewall S (2020)
    Minimizing bleeding events
    Eur Heart J Cardiovasc Pharmacother, 6 (5), 271-272
    DOI 10.1093/ehjcvp/pvaa100, PubMed 32932523
  52. Khatami M, Pope MK, Le Page S, Radic P, Schirripa V, Grundvold I, Atar D (2020)
    Cardioversion Safety - Are We Doing Enough?
    Cardiology, 145 (11), 740-745
    DOI 10.1159/000509343, PubMed 32898849
  53. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM, Minotti G (2020)
    The cancer patient and cardiology
    Eur J Heart Fail, 22 (12), 2290-2309
    DOI 10.1002/ejhf.1985, PubMed 32809231
  54. Johannessen TR, Vallersnes OM, Halvorsen S, Larstorp ACK, Mdala I, Atar D (2020)
    Pre-hospital One-Hour Troponin in a Low-Prevalence Population of Acute Coronary Syndrome: OUT-ACS study
    Open Heart, 7 (2)
    DOI 10.1136/openhrt-2020-001296, PubMed 32719074
  55. Ghanima W, Brodin E, Schultze A, Shepherd L, Lambrelli D, Ulvestad M, Ramagopalan S, Halvorsen S (2020)
    Incidence and prevalence of venous thromboembolism in Norway 2010-2017
    Thromb Res, 195, 165-168
    DOI 10.1016/j.thromres.2020.07.011, PubMed 32707359
  56. Bassand JP, Apenteng PN, Atar D, Camm AJ, Cools F, Corbalan R, Fitzmaurice DA, Fox KA, Goto S, Haas S, Hacke W, Jerjes-Sanchez C, Koretsune Y, Heuzey JL, Sawhney JP, Oh S, Stępińska J, Cate VT, Verheugt FW, Kayani G, Pieper KS, Kakkar AK, Garfield-Af Investigators FT (2020)
    GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke
    Future Cardiol, 17 (1), 19-38
    DOI 10.2217/fca-2020-0014, PubMed 32696663
  57. Birnbaum Y, Levine GN, French J, Kaski JC, Atar D, Alam M, Hasdai D, Jneid H, Uretsky BF (2020)
    Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?
    Cardiovasc Drugs Ther, 34 (6), 865-870
    DOI 10.1007/s10557-020-07039-0, PubMed 32671603
  58. Agewall S (2020)
    Can we offer tailor-made pharmacological treatment of patients with acute coronary syndrome?
    Eur Heart J Cardiovasc Pharmacother, 6 (4), 201-202
    DOI 10.1093/ehjcvp/pvaa075, PubMed 32668002
  59. Stensjøen AL, Hommerstad A, Halvorsen S, Arheden H, Engblom H, Erlinge D, Larsen AI, Sejersten Ripa M, Clemmensen P, Atar D, Hall TS (2020)
    Worst lead ST deviation and resolution of ST elevation at one hour for prediction of myocardial salvage, infarct size, and microvascular obstruction in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
    Ann Noninvasive Electrocardiol, 25 (6), e12784
    DOI 10.1111/anec.12784, PubMed 32592427
  60. Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, Liao X, Lonn E, Gerstein HC, Yusuf S, Brouwers FP, Asselbergs FW, van Gilst W, Anderssen SA, Grobbee DE, Kastelein JJP, Visseren FLJ, Ntaios G, Hatzitolios AI, Savopoulos C, Nieuwkerk PT, Stroes E, Walters M, Higgins P, Dawson J et al. (2020)
    Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients
    Circulation, 142 (7), 621-642
    DOI 10.1161/CIRCULATIONAHA.120.046361, PubMed 32546049
  61. Ødegaard KM, Hallén J, Lirhus SS, Melberg HO, Halvorsen S (2020)
    Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016
    ESC Heart Fail, 7 (4), 1917-1926
    DOI 10.1002/ehf2.12773, PubMed 32530563
  62. Agewall S (2018)
    Adherence to guidelines, compliance to treatment, and treatment quality
    Eur Heart J Cardiovasc Pharmacother, 4 (4), 189-190
    DOI 10.1093/ehjcvp/pvy033, PubMed 32420591
  63. Bogsrud MP, Øyri LKL, Halvorsen S, Atar D, Leren TP, Holven KB (2020)
    Prevalence of genetically verified familial hypercholesterolemia among young (<45 years) Norwegian patients hospitalized with acute myocardial infarction
    J Clin Lipidol, 14 (3), 339-345
    DOI 10.1016/j.jacl.2020.04.002, PubMed 32418822
  64. Agewall S (2020)
    Focus on subpopulations of atrial fibrillation patients
    Eur Heart J Cardiovasc Pharmacother, 6 (3), 131-132
    DOI 10.1093/ehjcvp/pvaa034, PubMed 32412082
  65. Chieffo A, Stefanini GG, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan GL, Gilard M, Halvorsen S, Huber K, James S, Neumann FJ, Möllmann H, Roffi M, Tavazzi G, Mauri Ferré J, Windecker S, Dudek D, Baumbach A (2020)
    EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic
    Eur Heart J, 41 (19), 1839-1851
    DOI 10.1093/eurheartj/ehaa381, PubMed 32405641
  66. Chieffo A, Stefanini GG, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan GL, Gilard M, Halvorsen S, Huber K, James S, Neumann FJ, Möllmann H, Roffi M, Tavazzi G, Ferré JM, Windecker S, Dudek D, Baumbach A (2020)
    EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic
    EuroIntervention, 16 (3), 233-246
    DOI 10.4244/EIJY20M05_01, PubMed 32404302
  67. Butt N, Bache-Mathiesen LK, Ushakova A, Nordrehaug JE, Jensen SE, Munk PS, Danchin N, Dubois-Rande JL, Hansen HS, Paganelli F, Corvoisier PL, Firat H, Erlinge D, Atar D, Larsen AI (2020)
    Pentraxin 3 in primary percutaneous coronary intervention for ST elevation myocardial infarction is associated with early irreversible myocardial damage : Kinetic profile, relationship to interleukin 6 and infarct size
    Eur Heart J Acute Cardiovasc Care, 9 (4), 302-312
    DOI 10.1177/2048872620923641, PubMed 32403934
  68. Täger T, Atar D, Agewall S, Katus HA, Grundtvig M, Cleland JGF, Clark AL, Fröhlich H, Frankenstein L (2020)
    Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
    Heart Fail Rev
    DOI 10.1007/s10741-020-09954-8, PubMed 32314085
  69. Kjeldsen SE, Halvorsen S, Wyller TB, Bath PM, Sandercock P (2020)
    Eivind Berge, MD, PhD, 1964-2020: Cardiologist Who Was Fighting Stroke
    Stroke, 51 (5), 1353-1355
    DOI 10.1161/STROKEAHA.120.029351, PubMed 32200755
  70. Langseth MS, Helseth R, Ritschel V, Hansen CH, Andersen GØ, Eritsland J, Halvorsen S, Fagerland MW, Solheim S, Arnesen H, Seljeflot I, Opstad TB (2020)
    Double-Stranded DNA and NETs Components in Relation to Clinical Outcome After ST-Elevation Myocardial Infarction
    Sci Rep, 10 (1), 5007
    DOI 10.1038/s41598-020-61971-7, PubMed 32193509
  71. Jortveit J, Halvorsen S, Langørgen J (2020)
    Pharmacy-dispensed drugs for secondary prevention after myocardial infarction
    Tidsskr Nor Laegeforen, 140 (4)
    DOI 10.4045/tidsskr.19.0416, PubMed 32192264
  72. Agewall S (2020)
    Lipids and antithrombotic treatment
    Eur Heart J Cardiovasc Pharmacother, 6 (2), 71
    DOI 10.1093/ehjcvp/pvaa014, PubMed 32176294
  73. Jortveit J, Pripp AH, Langørgen J, Halvorsen S (2020)
    Incidence, risk factors and outcome of young patients with myocardial infarction
    Heart, 106 (18), 1420-1426
    DOI 10.1136/heartjnl-2019-316067, PubMed 32111640
  74. Gorog DA, Price S, Sibbing D, Baumbach A, Capodanno D, Gigante B, Halvorsen S, Huber K, Lettino M, Leonardi S, Morais J, Rubboli A, Siller-Matula JM, Storey RF, Vranckx P, Rocca B (2021)
    Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
    Eur Heart J Cardiovasc Pharmacother, 7 (2), 125-140
    DOI 10.1093/ehjcvp/pvaa009, PubMed 32049278
  75. Tancin Lambert A, Kong XY, Ratajczak-Tretel B, Atar D, Russell D, Skjelland M, Bjerkeli V, Skagen K, Coq M, Schordan E, Firat H, Halvorsen B, Aamodt AH (2020)
    Biomarkers Associated with Atrial Fibrillation in Patients with Ischemic Stroke: A Pilot Study from the NOR-FIB Study
    Cerebrovasc Dis Extra, 10 (1), 11-20
    DOI 10.1159/000504529, PubMed 32028277
  76. Gorenek B, Halvorsen S, Kudaiberdieva G, Bueno H, Van Gelder IC, Lettino M, Marin F, Masip J, Mueller C, Okutucu S, Poess J, Potpara TS, Price S, Lip GYH (2020)
    Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology
    Eur Heart J Acute Cardiovasc Care, 9 (4), 348-357
    DOI 10.1177/2048872619894255, PubMed 31976747
  77. Stepinska J, Lettino M, Ahrens I, Bueno H, Garcia-Castrillo L, Khoury A, Lancellotti P, Mueller C, Muenzel T, Oleksiak A, Petrino R, Guimenez MR, Zahger D, Vrints CJ, Halvorsen S, de Maria E, Lip GY, Rossini R, Claeys M, Huber K (2020)
    Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association
    Eur Heart J Acute Cardiovasc Care, 9 (1), 76-89
    DOI 10.1177/2048872619885346, PubMed 31958018
  78. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG et al. (2020)
    Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
    J Am Coll Cardiol, 75 (2), 133-144
    DOI 10.1016/j.jacc.2019.10.057, PubMed 31948641
  79. Rutherford OW, Jonasson C, Ghanima W, Söderdahl F, Halvorsen S (2020)
    Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
    Eur Heart J Cardiovasc Pharmacother, 6 (2), 75-85
    DOI 10.1093/ehjcvp/pvz086, PubMed 31942972
  80. Aamodt IT, Lycholip E, Celutkiene J, von Lueder T, Atar D, Falk RS, Hellesø R, Jaarsma T, Strömberg A, Lie I (2020)
    Self-Care Monitoring of Heart Failure Symptoms and Lung Impedance at Home Following Hospital Discharge: Longitudinal Study
    J Med Internet Res, 22 (1), e15445
    DOI 10.2196/15445, PubMed 31909717
  81. Agewall S (2020)
    Focus on pharma in acute coronary syndrome
    Eur Heart J Cardiovasc Pharmacother, 6 (1), 1-2
    DOI 10.1093/ehjcvp/pvz074, PubMed 31909430
  82. Garcia DA, Fisher DA, Mulder H, Wruck L, De Caterina R, Halvorsen S, Granger CB, Held C, Wallentin L, Alexander JH, Lopes RD (2019)
    Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
    Am Heart J, 221, 1-8
    DOI 10.1016/j.ahj.2019.10.013, PubMed 31896036
  83. Lunde NN, Gregersen I, Ueland T, Shetelig C, Holm S, Kong XY, Michelsen AE, Otterdal K, Yndestad A, Broch K, Gullestad L, Nyman TA, Bendz B, Eritsland J, Hoffmann P, Skagen K, Gonçalves I, Nilsson J, Grenegård M, Poreba M, Drag M, Seljeflot I, Sporsheim B, Espevik T, Skjelland M et al. (2019)
    Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages
    Atherosclerosis, 296, 74-82
    DOI 10.1016/j.atherosclerosis.2019.12.008, PubMed 31870625
  84. Helseth R, Shetelig C, Andersen GØ, Langseth MS, Limalanathan S, Opstad TB, Arnesen H, Hoffmann P, Eritsland J, Seljeflot I (2019)
    Neutrophil Extracellular Trap Components Associate with Infarct Size, Ventricular Function, and Clinical Outcome in STEMI
    Mediators Inflamm, 2019, 7816491
    DOI 10.1155/2019/7816491, PubMed 31772506
  85. Atar D, Berge E, Le Heuzey JY, Virdone S, Camm AJ, Steffel J, Gibbs H, Goldhaber SZ, Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Bassand JP, Kakkar AK, GARFIELD-AF Investigators (2020)
    The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events
    Europace, 22 (2), 195-204
    DOI 10.1093/europace/euz292, PubMed 31747004
  86. Bjørnnes AK, Moons P, Parry M, Halvorsen S, Tønnessen T, Lie I (2019)
    Experiences of informal caregivers after cardiac surgery: a systematic integrated review of qualitative and quantitative studies
    BMJ Open, 9 (11), e032751
    DOI 10.1136/bmjopen-2019-032751, PubMed 31719093
  87. Bhatt AS, Luo N, Solomon N, Pagidipati NJ, Ambrosio G, Green JB, McGuire DK, Standl E, Cornel JH, Halvorsen S, Lopes RD, White HD, Holman RR, Peterson ED, Mentz RJ, TECOS Study Group (2019)
    International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS
    Am Heart J, 218, 57-65
    DOI 10.1016/j.ahj.2019.08.016, PubMed 31707329
  88. Kvakkestad KM, Gran JM, Eritsland J, Holst Hansen C, Fossum E, Andersen GØ, Halvorsen S (2019)
    Long-Term Survival after Invasive or Conservative Strategy in Elderly Patients with non-ST-Elevation Myocardial Infarction: A Prospective Cohort Study
    Cardiology, 144 (3-4), 79-89
    DOI 10.1159/000503442, PubMed 31689705
  89. Gelbenegger G, Postula M, Pecen L, Halvorsen S, Lesiak M, Schoergenhofer C, Jilma B, Hengstenberg C, Siller-Matula JM (2019)
    Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
    BMC Med, 17 (1), 198
    DOI 10.1186/s12916-019-1428-0, PubMed 31679516
  90. Bahls M, Lorenz MW, Dörr M, Gao L, Kitagawa K, Tuomainen TP, Agewall S, Berenson G, Catapano AL, Norata GD, Bots ML, van Gilst W, Asselbergs FW, Brouwers FP, Uthoff H, Sander D, Poppert H, Hecht Olsen M, Empana JP, Schminke U, Baldassarre D, Veglia F, Franco OH, Kavousi M, de Groot E et al. (2019)
    Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium
    Eur J Prev Cardiol, 27 (3), 234-243
    DOI 10.1177/2047487319877078, PubMed 31619084
  91. Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, Heizer G, Goodman SG, Darius H, Jones WS, Aschermann M, Brieger D, Cura F, Engstrøm T, Fridrich V, Halvorsen S, Huber K, Kang HJ, Leiva-Pons JL, Lewis BS, Malaga G, Meneveau N, Merkely B, Milicic D, Morais J et al. (2019)
    Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial
    Circulation, 140 (23), 1921-1932
    DOI 10.1161/CIRCULATIONAHA.119.043308, PubMed 31557056
  92. Agewall S (2019)
    European Heart Journal - Cardiovascular Pharmacotherapy has received its first Impact Factor of 6.723
    Eur Heart J Cardiovasc Pharmacother, 5 (4), 183-184
    DOI 10.1093/ehjcvp/pvz041, PubMed 31531677
  93. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ et al. (2020)
    2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
    Eur Heart J, 41 (3), 407-477
    DOI 10.1093/eurheartj/ehz425, PubMed 31504439
  94. Marciniak TA, Atar D, Serebruany V (2019)
    Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?
    Am J Med, 133 (3), 347-351
    DOI 10.1016/j.amjmed.2019.07.046, PubMed 31442391
  95. Allencherril J, Jneid H, Atar D, Alam M, Levine G, Kloner RA, Birnbaum Y (2019)
    Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon
    Cardiovasc Drugs Ther, 33 (5), 589-597
    DOI 10.1007/s10557-019-06901-0, PubMed 31418141
  96. Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, Meroni PL (2020)
    Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology
    Eur Heart J Cardiovasc Pharmacother, 6 (2), 104-114
    DOI 10.1093/ehjcvp/pvz033, PubMed 31397840
  97. Savarese G, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS (2020)
    Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases
    Eur Heart J Cardiovasc Pharmacother, 6 (2), 86-93
    DOI 10.1093/ehjcvp/pvz036, PubMed 31392312
  98. Al-Ani A, Hoffmann P, von Lueder T, Opdahl A (2019)
    Safety and efficacy of hybrid vascular closure technique using both a suture- and collagen-mediated closure device after transfemoral transcatheter aortic valve implantation
    Catheter Cardiovasc Interv, 95 (6), 1171-1175
    DOI 10.1002/ccd.28419, PubMed 31379116
  99. Frankenstein L, Seide S, Täger T, Jensen K, Fröhlich H, Clark AL, Seiz M, Katus HA, Nee P, Uhlmann L, Naci H, Atar D (2020)
    Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials
    Heart Fail Rev, 25 (2), 161-171
    DOI 10.1007/s10741-019-09832-y, PubMed 31364027
  100. Fox KAA, Metra M, Morais J, Atar D (2019)
    The myth of 'stable' coronary artery disease
    Nat Rev Cardiol, 17 (1), 9-21
    DOI 10.1038/s41569-019-0233-y, PubMed 31358978
  101. Marti HP, Serebruany V, Atar D (2019)
    Challenging Anticoagulation in Advanced Renal Failure
    Am J Med, 132 (11), 1258-1259
    DOI 10.1016/j.amjmed.2019.07.002, PubMed 31356767
  102. Hokstad I, Deyab G, Wang Fagerland M, Lyberg T, Hjeltnes G, Førre Ø, Agewall S, Mollnes TE, Hollan I (2019)
    Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study
    PLoS One, 14 (7), e0220079
    DOI 10.1371/journal.pone.0220079, PubMed 31335881
  103. Ahrens I, Averkov O, Zúñiga EC, Fong AYY, Alhabib KF, Halvorsen S, Abdul Kader MABSK, Sanz-Ruiz R, Welsh R, Yan H, Aylward P (2019)
    Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox
    Clin Cardiol, 42 (10), 1028-1040
    DOI 10.1002/clc.23232, PubMed 31317575
  104. Verheugt FWA, Ambrosio G, Atar D, Bassand JP, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK, GARFIELD-AF Investigators (2019)
    Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF
    Am J Med, 132 (12), 1431-1440.e7
    DOI 10.1016/j.amjmed.2019.06.008, PubMed 31306621
  105. Pradhan B, Kjellstrom T, Atar D, Sharma P, Kayastha B, Bhandari G, Pradhan PK (2019)
    Heat Stress Impacts on Cardiac Mortality in Nepali Migrant Workers in Qatar
    Cardiology, 143 (1), 37-48
    DOI 10.1159/000500853, PubMed 31302648
  106. Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S (2020)
    The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials
    Eur Heart J Cardiovasc Pharmacother, 6 (2), 97-103
    DOI 10.1093/ehjcvp/pvz029, PubMed 31298686
  107. Hall TS, von Lueder TG, Zannad F, Rossignol P, Duarte K, Chouihed T, Solomon SD, Dickstein K, Atar D, Agewall S, Girerd N, High-Risk Myocardial Infarction Database Initiative investigators (2019)
    Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction
    Am Heart J, 215, 83-90
    DOI 10.1016/j.ahj.2019.06.004, PubMed 31291604
  108. Nordlund D, Engblom H, Bonnet JL, Hansen HS, Atar D, Erlinge D, Ekelund U, Heiberg E, Carlsson M, Arheden H (2019)
    Gender but not diabetes, hypertension or smoking affects infarct evolution in ST-elevation myocardial infarction patients - data from the CHILL-MI, MITOCARE and SOCCER trials
    BMC Cardiovasc Disord, 19 (1), 161
    DOI 10.1186/s12872-019-1139-7, PubMed 31269907
  109. Ratajczak-Tretel B, Lambert AT, Johansen H, Halvorsen B, Bjerkeli V, Russell D, Sandset EC, Ihle-Hansen H, Eriksen E, Næss H, Novotny V, Khanevski AN, Truelsen TC, Idicula T, Ægidius KL, Tobro H, Krogseth SB, Ihle-Hansen H, Hagberg G, Kruuse C, Arntzen K, Bakkejord GK, Villseth M, Nakstad I, Eldøen G et al. (2019)
    Atrial fibrillation in cryptogenic stroke and transient ischaemic attack - The Nordic Atrial Fibrillation and Stroke (NOR-FIB) Study: Rationale and design
    Eur Stroke J, 4 (2), 172-180
    DOI 10.1177/2396987319837089, PubMed 31259265
  110. Agewall S (2019)
    Antiplatelet treatment in acute coronary syndrome. Still an issue
    Eur Heart J Cardiovasc Pharmacother, 5 (3), 125-126
    DOI 10.1093/ehjcvp/pvz018, PubMed 31210265
  111. Fossum S, Næss Ø, Halvorsen S, Tell GS, Vikanes ÅV (2019)
    Long-term cardiovascular morbidity following hyperemesis gravidarum: A Norwegian nationwide cohort study
    PLoS One, 14 (6), e0218051
    DOI 10.1371/journal.pone.0218051, PubMed 31188868
  112. von Lueder TG, Atar D, Agewall S, Jensen JK, Hopper I, Kotecha D, Mentz RJ, Kim MH, Serebruany VL (2019)
    All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System
    Am J Ther, 26 (6), e671-e678
    DOI 10.1097/MJT.0000000000000883, PubMed 31145139
  113. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A (2019)
    Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke
    Eur Heart J Cardiovasc Pharmacother, 5 (3), 171-180
    DOI 10.1093/ehjcvp/pvz016, PubMed 31119266
  114. Fernandes A, McEvoy JW, Halvorsen S (2019)
    "Doctor, Should I Keep Taking an Aspirin a Day?"
    N Engl J Med, 380 (20), 1967-1970
    DOI 10.1056/NEJMclde1903004, PubMed 31091380
  115. Hjort M, Eggers KM, Lindhagen L, Agewall S, Brolin EB, Collste O, Daniel M, Ekenbäck C, Frick M, Henareh L, Hofman-Bang C, Malmqvist K, Spaak J, Sörensson P, Y-Hassan S, Tornvall P, Lindahl B (2019)
    Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries
    Clin Chem, 65 (8), 1023-1030
    DOI 10.1373/clinchem.2018.301085, PubMed 31072836
  116. Hausvater A, Pasupathy S, Tornvall P, Gandhi H, Tavella R, Beltrame J, Agewall S, Ekenbäck C, Brolin EB, Hochman JS, Collste O, Reynolds HR (2019)
    ST-segment elevation and cardiac magnetic resonance imaging findings in myocardial infarction with non-obstructive coronary arteries
    Int J Cardiol, 287, 128-131
    DOI 10.1016/j.ijcard.2019.04.028, PubMed 31003795
  117. Jortveit J, Pripp AH, Langørgen J, Halvorsen S (2019)
    Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction
    Eur J Prev Cardiol, 26 (13), 1373-1382
    DOI 10.1177/2047487319841940, PubMed 30966816
  118. Kotecha D, Flather MD, Atar D, Collins P, Pepper J, Jenkins E, Reid CM, Eccleston D, Alternative Risk Markers in Coronary Artery Disease (ARM-CAD) Study (2019)
    B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease
    BMC Med, 17 (1), 72
    DOI 10.1186/s12916-019-1306-9, PubMed 30943979
  119. Hoffmann P, Al-Ani A, von Lueder T, Skoe ØW, Tran TT, Opdahl A (2018)
    Late Pseudoaneurysm After Access Site Closure with Manta in Transfemoral Aortic Valve Implantation
    EJVES Short Rep, 42, 34-36
    DOI 10.1016/j.ejvssr.2018.10.003, PubMed 30931405
  120. Jortveit J, Halvorsen S, Kaldal A, Pripp AH, Govatsmark RES, Langørgen J (2019)
    Unsatisfactory risk factor control and high rate of new cardiovascular events in patients with myocardial infarction and prior coronary artery disease
    BMC Cardiovasc Disord, 19 (1), 71
    DOI 10.1186/s12872-019-1062-y, PubMed 30922234
  121. Agewall S (2019)
    European Heart Journal - Cardiovascular Pharmacotherapy: now accepted for an official Impact Factor
    Eur Heart J Cardiovasc Pharmacother, 5 (2), 59
    DOI 10.1093/ehjcvp/pvz009, PubMed 30874813
  122. Agewall S (2019)
    Unsolved issues in oral anticoagulation treatment in atrial fibrillation
    Eur Heart J Cardiovasc Pharmacother, 5 (2), 60-61
    DOI 10.1093/ehjcvp/pvz008, PubMed 30874812
  123. Atar D (2019)
    Editor's Note
    Cardiology, 142 (1), 1
    DOI 10.1159/000497089, PubMed 30852568
  124. Rosano GMC, Spoletini I, Agewall S (2019)
    Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
    Eur Heart J Suppl, 21 (Suppl A), A28-A33
    DOI 10.1093/eurheartj/suy035, PubMed 30837802
  125. Täger T, Fröhlich H, Grundtvig M, Seiz M, Schellberg D, Goode K, Kazmi S, Hole T, Katus HA, Atar D, Cleland JGF, Agewall S, Clark AL, Frankenstein L (2019)
    Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis
    Int J Cardiol, 289, 83-90
    DOI 10.1016/j.ijcard.2019.01.109, PubMed 30827731
  126. Serebruany VL, Marciniak TA, Atar D (2019)
    Predicting clinical outcomes after clopidogrel use: easier to postulate than to prove and implement
    Pol Arch Intern Med, 129 (2), 78-79
    DOI 10.20452/pamw.4467, PubMed 30816102
  127. Fröhlich H, Rosenfeld N, Täger T, Goode K, Kazmi S, Hole T, Katus HA, Atar D, Cleland JGF, Agewall S, Clark AL, Frankenstein L, Grundtvig M (2019)
    Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe
    Heart, 105 (16), 1252-1259
    DOI 10.1136/heartjnl-2018-314256, PubMed 30792238
  128. Atar D, Grundvold I (2019)
    On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient?
    Eur Heart J, 40 (19), 1501-1503
    DOI 10.1093/eurheartj/ehz014, PubMed 30753396
  129. Hill JA, Agewall S, Baranchuk A, Booz GW, Borer JS, Camici PG, Chen PS, Dominiczak AF, Erol Ç, Grines CL, Gropler R, Guzik TJ, Heinemann MK, Iskandrian AE, Knight BP, London B, Lüscher TF, Metra M, Musunuru K, Nallamothu BK, Natale A, Saksena S, Picard MH, Rao SV, Remme WJ et al. (2019)
    Medical Misinformation: Vet the Message!
    J Cardiovasc Pharmacol, 73 (2), 61-62
    DOI 10.1097/FJC.0000000000000648, PubMed 30730472
  130. Aamodt IT, Lycholip E, Celutkiene J, Strömberg A, Atar D, Falk RS, von Lueder T, Hellesø R, Jaarsma T, Lie I (2019)
    Health Care Professionals' Perceptions of Home Telemonitoring in Heart Failure Care: Cross-Sectional Survey
    J Med Internet Res, 21 (2), e10362
    DOI 10.2196/10362, PubMed 30724744
  131. Hill JA, Agewall S, Baranchuk A, Booz GW, Borer JS, Camici PG, Chen PS, Dominiczak AF, Erol Ç, Grines CL, Gropler R, Guzik TJ, Heinemann MK, Iskandrian AE, Knight BP, London B, Lüscher TF, Metra M, Musunuru K, Nallamothu BK, Natale A, Saksena S, Picard MH, Rao SV, Remme WJ et al. (2019)
    Medical misinformation: Vet the message!
    Heart Rhythm, 16 (3), 332-333
    DOI 10.1016/j.hrthm.2018.12.030, PubMed 30703343
  132. Kjeldsen SE, Atar D, von Lueder TG (2019)
    Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy
    Eur Heart J Cardiovasc Pharmacother, 5 (2), 122-123
    DOI 10.1093/ehjcvp/pvz005, PubMed 30698668
  133. Hill JA, Agewall S, Baranchuk A, Booz GW, Borer JS, Camici PG, Chen PS, Dominiczak AF, Erol Ç, Grines CL, Gropler R, Guzik TJ, Heinemann MK, Iskandrian AE, Knight BP, London B, Lüscher TF, Metra M, Musunuru K, Nallamothu BK, Natale A, Saksena S, Picard MH, Rao SV, Remme WJ et al. (2019)
    Medical misinformation: vet the message!
    Eur Heart J Qual Care Clin Outcomes, 5 (2), 83-84
    DOI 10.1093/ehjqcco/qcy057, PubMed 30689789
  134. Hill JA, Agewall S, Baranchuk A, Booz GW, Borer JS, Camici PG, Chen PS, Dominiczak AF, Erol Ç, Grines CL, Gropler R, Guzik TJ, Heinemann MK, Iskandrian AE, Knight BP, London B, Lüscher TF, Metra M, Musunuru K, Nallamothu BK, Natale A, Saksena S, Picard MH, Rao SV, Remme WJ et al. (2019)
    Medical misinformation: vet the message!
    Eur Heart J Cardiovasc Pharmacother, 5 (2), 62-63
    DOI 10.1093/ehjcvp/pvz001, PubMed 30689786
  135. Hill JA, Agewall S, Baranchuk A, Booz GW, Borer JS, Camici PG, Chen PS, Dominiczak AF, Erol Ç, Grines CL, Gropler R, Guzik TJ, Heinemann MK, Iskandrian AE, Knight BP, London B, Lüscher TF, Metra M, Musunuru K, Nallamothu BK, Natale A, Saksena S, Picard MH, Rao SV, Remme WJ et al. (2019)
    Medical misinformation: vet the message!
    Cardiovasc Res (in press)
    DOI 10.1093/cvr/cvz007, PubMed 30689762
  136. Hoffmann P, Al-Ani A, von Lueder T, Hoffmann J, Majak P, Hagen O, Loose H, Kløw NE, Opdahl A (2018)
    Access site complications after transfemoral aortic valve implantation - a comparison of Manta and ProGlide
    CVIR Endovasc, 1 (1), 20
    DOI 10.1186/s42155-018-0026-0, PubMed 30652151
  137. Agewall S (2019)
    Old and new drugs in cardiovascular pharmacotherapy
    Eur Heart J Cardiovasc Pharmacother, 5 (1), 1-2
    DOI 10.1093/ehjcvp/pvy046, PubMed 30615170
  138. Rutherford OW, Jonasson C, Ghanima W, Holst R, Halvorsen S (2018)
    New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
    Open Heart, 5 (2), e000931
    DOI 10.1136/openhrt-2018-000931, PubMed 30613418
  139. Stubnova V, Os I, Høieggen A, Solbu MD, Grundtvig M, Westheim AS, Atar D, Waldum-Grevbo B (2019)
    Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure
    BMC Cardiovasc Disord, 19 (1), 4
    DOI 10.1186/s12872-018-0989-8, PubMed 30611196
  140. Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB, ARISTOTLE Investigators (2018)
    Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial
    Am Heart J, 208, 123-131
    DOI 10.1016/j.ahj.2018.09.017, PubMed 30579505
  141. Bugge C, Sether EM, Pahle A, Halvorsen S, Sonbo Kristiansen I (2018)
    Diagnosing heart failure with NT-proBNP point-of-care testing: lower costs and better outcomes. A decision analytic study
    BJGP Open, 2 (3), bjgpopen18X101596
    DOI 10.3399/bjgpopen18X101596, PubMed 30564729
  142. Allencherril J, Alam M, Levine G, Jneid H, Atar D, Kloner RA, Birnbaum Y (2018)
    Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?
    J Cardiovasc Pharmacol Ther, 24 (3), 215-224
    DOI 10.1177/1074248418812167, PubMed 30563349
  143. Tjora S, Hall TS, Larstorp AC, Hallen J, Atar D (2018)
    Increases in Circulating Cardiac Troponin Are Not Always Associated with Myocardial Cell Death
    Clin Lab, 64 (11)
    DOI 10.7754/Clin.Lab.2018.180615, PubMed 30549980
  144. Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernæs KH, Vethe NT, Prescott E, Jensen SE, Rødevand O, Jortveit J, Bendz B, Schirmer H, Køber L, Bøtker HE, Larsen AI, Vikenes K, Steigen T, Wiseth R, Pedersen T, Edvardsen T, Otterstad JE, Atar D (2018)
    BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study
    Am Heart J, 208, 37-46
    DOI 10.1016/j.ahj.2018.10.005, PubMed 30530121
  145. Nero D, Agewall S, Daniel M, Caidahl K, Collste O, Ekenbäck C, Frick M, Henareh L, Jernberg T, Malmqvist K, Schenck-Gustafsson K, Spaak J, Sörensson P, Sundin Ö, Y-Hassan S, Hofman-Bang C, Tornvall P (2018)
    Personality Traits in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries
    Am J Med, 132 (3), 374-381.e1
    DOI 10.1016/j.amjmed.2018.11.010, PubMed 30503881
  146. Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L (2018)
    Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
    Open Heart, 5 (2), e000908
    DOI 10.1136/openhrt-2018-000908, PubMed 30487982
  147. Bethke A, Shanmuganathan L, Shetelig C, Swanson D, Andersen GØ, Eritsland J, Kløw NE, Hoffmann P (2018)
    MR findings of microvascular perfusion in infarcted and remote myocardium early after successful primary PCI
    PLoS One, 13 (11), e0206723
    DOI 10.1371/journal.pone.0206723, PubMed 30412607
  148. Navarese EP, Andreotti F, Raggi P, Kolodziejczak M, Buffon A, Bliden K, Tantry U, Kubica J, Sardella G, Lauten A, Agewall S, Gurbel PA, Brouwer MA (2019)
    Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review
    Eur Heart J Cardiovasc Pharmacother, 5 (1), 47-54
    DOI 10.1093/ehjcvp/pvy038, PubMed 30247574
  149. Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A (2018)
    Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
    Heart, 105 (3), 235-242
    DOI 10.1136/heartjnl-2018-313351, PubMed 30209126
  150. Serebruany VL, Hall TS, Atar D, Agewall S, Hyun Kim M, Geudelin B, Lomakin N, Marciniak TA (2019)
    Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System
    Eur Heart J Cardiovasc Pharmacother, 5 (4), 210-215
    DOI 10.1093/ehjcvp/pvy035, PubMed 30192939
  151. Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, Atar D, Otterstad JE (2019)
    Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis
    Eur Heart J Cardiovasc Pharmacother, 5 (1), 12-20
    DOI 10.1093/ehjcvp/pvy034, PubMed 30192930
  152. Hall TS, von Lueder TG, Zannad F, Rossignol P, Duarte K, Chouihed T, Dickstein K, Atar D, Agewall S, Girerd N, High-Risk Myocardial Infarction Database Initiative investigators (2018)
    Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction
    Int J Cardiol, 272, 260-266
    DOI 10.1016/j.ijcard.2018.07.137, PubMed 30144995
  153. Niessner A, Agewall S (2018)
    Critical appraisal of the COMPASS trial
    Eur Heart J Cardiovasc Pharmacother, 4 (4), 191-192
    DOI 10.1093/ehjcvp/pvy027, PubMed 30113628
  154. Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, Ceconi C, Savarese G, Rosano G, Wassmann S, Niessner A, Schmidt TA, Saely CH, Baumgartner I, Tamargo J (2018)
    Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review
    Eur Heart J Cardiovasc Pharmacother, 4 (4), 230-236
    DOI 10.1093/ehjcvp/pvy028, PubMed 30099530
  155. Jia X, Heiberg E, Sejersten Ripa M, Engblom H, Carlsson M, Halvorsen S, Arheden H, Atar D, Clemmensen P, Birnbaum Y (2018)
    Cardiac Magnetic Resonance Evaluation of the Extent of Myocardial Injury in Patients with Inferior ST Elevation Myocardial Infarction and Concomitant ST Depression in Leads V1-V3: Analysis from the MITOCARE Study
    Cardiology, 140 (3), 178-185
    DOI 10.1159/000491745, PubMed 30099440
  156. Berwanger O, Abdelhamid M, Alexander T, Alzubaidi A, Averkov O, Aylward P, Contreras Zúñiga E, Halvorsen S, Iglesias R, A Sk Abdul Kader M, Zubaid M, AlHabib KF (2018)
    Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study
    Clin Cardiol, 41 (10), 1322-1327
    DOI 10.1002/clc.23043, PubMed 30098028
  157. Ruddox V, Otterstad JE, Atar D, Bendz B, Edvardsen T (2018)
    In Current Clinical Practice, after Percutaneous Coronary Intervention for Acute Myocardial Infarction, Are β-Blockers Prescribed for Heart Failure or as Secondary Prevention? A Pilot Study
    Cardiology, 140 (3), 152-154
    DOI 10.1159/000490656, PubMed 30089282
  158. Mayerhofer CCK, Awoyemi AO, Moscavitch SD, Lappegård KT, Hov JR, Aukrust P, Hovland A, Lorenzo A, Halvorsen S, Seljeflot I, Gullestad L, Trøseid M, Broch K (2018)
    Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial
    ESC Heart Fail, 5 (5), 977-984
    DOI 10.1002/ehf2.12332, PubMed 30088346
  159. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M, Huber K, ESC Scientific Document Group (2019)
    2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)
    Europace, 21 (2), 192-193
    DOI 10.1093/europace/euy174, PubMed 30052888
  160. Agewall S (2018)
    New input on antiplatelet treatment and registry studies
    Eur Heart J Cardiovasc Pharmacother, 4 (3), 129-130
    DOI 10.1093/ehjcvp/pvy016, PubMed 30052852
  161. Lewis BS, Atar D (2018)
    Peripheral arterial disease and limb salvage: a new arena for the cardiologist
    Eur Heart J Cardiovasc Pharmacother, 4 (3), 136-137
    DOI 10.1093/ehjcvp/pvy014, PubMed 30052851
  162. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
    Author's response to: letter to the editor
    Heart Fail Rev, 23 (5), 819
    DOI 10.1007/s10741-018-9728-6, PubMed 30043131
  163. von Lueder TG, Agewall S (2018)
    The burden of heart failure in the general population: a clearer and more concerning picture
    J Thorac Dis, 10 (Suppl 17), S1934-S1937
    DOI 10.21037/jtd.2018.04.153, PubMed 30023084
  164. Allencherril J, Fakhri Y, Engblom H, Heiberg E, Carlsson M, Dubois-Rande JL, Halvorsen S, Hall TS, Larsen AI, Jensen SE, Arheden H, Atar D, Clemmensen P, Ripa MS, Birnbaum Y (2018)
    Correlation of anteroseptal ST elevation with myocardial infarction territories through cardiovascular magnetic resonance imaging
    J Electrocardiol, 51 (4), 563-568
    DOI 10.1016/j.jelectrocard.2018.03.016, PubMed 29996989
  165. Bethke A, Shanmuganathan L, Andersen GØ, Eritsland J, Swanson D, Kløw NE, Hoffmann P (2018)
    Microvascular perfusion in infarcted and remote myocardium after successful primary PCI: angiographic and CMR findings
    Eur Radiol, 29 (2), 941-950
    DOI 10.1007/s00330-018-5588-7, PubMed 29980929
  166. Shetelig C, Limalanathan S, Hoffmann P, Seljeflot I, Gran JM, Eritsland J, Andersen GØ (2018)
    Association of IL-8 With Infarct Size and Clinical Outcomes in Patients With STEMI
    J Am Coll Cardiol, 72 (2), 187-198
    DOI 10.1016/j.jacc.2018.04.053, PubMed 29976293
  167. Allencherril J, Fakhri Y, Engblom H, Heiberg E, Carlsson M, Dubois-Rande JL, Halvorsen S, Hall TS, Larsen AI, Jensen SE, Arheden H, Atar D, Clemmensen P, Ripa MS, Birnbaum Y (2018)
    The significance of ST-elevation in aVL in anterolateral myocardial infarction: An assessment by cardiac magnetic resonance imaging
    Ann Noninvasive Electrocardiol, 23 (6), e12580
    DOI 10.1111/anec.12580, PubMed 29971868
  168. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
    Response to the editor
    Heart Fail Rev (in press)
    DOI 10.1007/s10741-018-9723-y, PubMed 29968222
  169. Fossum S, Halvorsen S, Vikanes ÅV, Roseboom TJ, Ariansen I, Næss Ø (2018)
    Cardiovascular risk profile at the age of 40-45 in women with previous hyperemesis gravidarum or hypertensive disorders in pregnancy: A population-based study
    Pregnancy Hypertens, 12, 129-135
    DOI 10.1016/j.preghy.2018.04.013, PubMed 29858105
  170. Orrem HL, Shetelig C, Ueland T, Limalanathan S, Nilsson PH, Husebye T, Aukrust P, Seljeflot I, Hoffmann P, Eritsland J, Mollnes TE, Andersen GØ, Yndestad A (2018)
    Soluble IL-1 receptor 2 is associated with left ventricular remodelling in patients with ST-elevation myocardial infarction
    Int J Cardiol, 268, 187-192
    DOI 10.1016/j.ijcard.2018.05.032, PubMed 29853279
  171. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS (2018)
    Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology
    Eur Heart J Cardiovasc Pharmacother, 4 (3), 180-188
    DOI 10.1093/ehjcvp/pvy015, PubMed 29726985
  172. Pahlm U, Seemann F, Engblom H, Gyllenhammar T, Halvorsen S, Hansen HS, Erlinge D, Atar D, Heiberg E, Arheden H, Carlsson M (2018)
    Longitudinal left ventricular function is globally depressed within a week of STEMI
    Clin Physiol Funct Imaging, 38 (6), 1029-1037
    DOI 10.1111/cpf.12521, PubMed 29701310
  173. Hansen CH, Ritschel V, Andersen GØ, Halvorsen S, Eritsland J, Arnesen H, Seljeflot I (2018)
    Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction
    Clin Appl Thromb Hemost, 24 (7), 1088-1094
    DOI 10.1177/1076029618764847, PubMed 29695176
  174. Aboyans V, Björck M, Brodmann M, Collet JP, Czerny M, De Carlo M, Naylor AR, Roffi M, Tendera M, Vlachopoulos C, Ricco JB, Task Force for the 2017 ESC Guidelines for the diagnosis and management of Peripheral Arterial Diseases, in collaboration with the ESVS, Document Reviewers, Widimsky P, Kolh P, Dick F, Vega de Ceniga M, Piepoli MF, Sievert H, Sulzenko J, Esc Committee For Practice Guidelines Cpg, Windecker S, Aboyans V, Agewall S, Barbato E et al. (2018)
    Questions and Answers on Diagnosis and Management of Patients with Peripheral Arterial Diseases: A Companion Document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
    Eur J Vasc Endovasc Surg, 55 (4), 457-464
    DOI 10.1016/j.ejvs.2017.08.014, PubMed 29628287
  175. Jia X, Heiberg E, Ripa MS, Engblom H, Halvorsen S, Arheden H, Atar D, Clemmensen P, Birnbaum Y (2018)
    Correlation of ST changes in leads V4-V6 to area of ischemia by CMR in inferior STEMI
    Scand Cardiovasc J, 52 (4), 189-195
    DOI 10.1080/14017431.2018.1458145, PubMed 29595340
  176. Andresen K, Atar D, Gjertsen E, Ghanima W, Roseth S, Johansen OE (2018)
    Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants
    Scand Cardiovasc J, 52 (3), 156-162
    DOI 10.1080/14017431.2018.1453613, PubMed 29569500
  177. Agewall S (2018)
    Cardiovascular pharmacotherapy and real-world data
    Eur Heart J Cardiovasc Pharmacother, 4 (2), 65-66
    DOI 10.1093/ehjcvp/pvy008, PubMed 29554294
  178. Bonaca MP, De Ferrari GM, Atar D, Bash LD, Lautsch D, Bohula EA, Horack M, Brudi P, Ferrieres J, Gitt AK (2018)
    How does the TRS 2°P score relate to real-world patients?
    Eur Heart J Cardiovasc Pharmacother, 4 (2), 72-74
    DOI 10.1093/ehjcvp/pvy004, PubMed 29554293
  179. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
    The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
    Heart Fail Rev, 23 (3), 303-323
    DOI 10.1007/s10741-018-9685-0, PubMed 29516230
  180. Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet JP, Grove EL, Halvorsen S, Huber K, Morais J, Patrono C, Rubboli A, Seljeflot I, Sibbing D, Siegbahn A, Ten Berg J, Vilahur G, Verheugt FWA, Wallentin L, Weiss TW, Wojta J, Storey RF (2018)
    Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis
    Eur Heart J, 39 (19), 1672-1686f
    DOI 10.1093/eurheartj/ehy066, PubMed 29509886
  181. Wisløff T, Atar D (2016)
    Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
    Eur Heart J Qual Care Clin Outcomes, 2 (1), 52-57
    DOI 10.1093/ehjqcco/qcv023, PubMed 29474586
  182. Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS, Verheugt FWA, Vinereanu D, Bahit MC, Halvorsen S, Huber K, Parkhomenko A, Granger CB, Lopes RD, Alexander JH (2017)
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial
    Am Heart J, 197, 133-141
    DOI 10.1016/j.ahj.2017.11.005, PubMed 29447773
  183. Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, van Gelder I, Gorenek B, Kaski JC, Kjeldsen K, Lip GYH, Merkely B, Okumura K, Piccini JP, Potpara T, Poulsen BK, Saba M, Savelieva I, Tamargo JL, Wolpert C, ESC Scientific Document Group (2018)
    Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP)
    Europace, 20 (5), 731-732an
    DOI 10.1093/europace/eux373, PubMed 29438514
  184. Pol T, Held C, Westerbergh J, Lindbäck J, Alexander JH, Alings M, Erol C, Goto S, Halvorsen S, Huber K, Hanna M, Lopes RD, Ruzyllo W, Granger CB, Hijazi Z (2018)
    Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
    J Am Heart Assoc, 7 (3)
    DOI 10.1161/JAHA.117.007444, PubMed 29419390
  185. Agewall S (2018)
    Cardiovascular pharmacotherapy
    Eur Heart J Cardiovasc Pharmacother, 4 (1), 1
    DOI 10.1093/ehjcvp/pvx036, PubMed 29315398
  186. Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, Benussi S, Blomstrom-Lundqvist C, Borggrefe M, Boriani G, Brandes A, Calkins H, Casadei B, Castellá M, Chua W, Crijns H, Dobrev D, Fabritz L, Feuring M, Freedman B, Gerth A et al. (2018)
    Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference
    Europace, 20 (3), 395-407
    DOI 10.1093/europace/eux318, PubMed 29300976
  187. Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, van Eickels M, Kakkar AK, GARFIELD-AF Investigators (2018)
    Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry
    Eur Heart J, 39 (6), 464-473
    DOI 10.1093/eurheartj/ehx730, PubMed 29281086
  188. Kaluzna-Oleksy M, Aunan K, Rao-Skirbekk S, Kjellstrom T, Ezekowitz JA, Agewall S, Atar D (2017)
    Impact of climate and air pollution on acute coronary syndromes: an update from the European Society of Cardiology Congress 2017
    Scand Cardiovasc J, 52 (1), 1-3
    DOI 10.1080/14017431.2017.1405069, PubMed 29202608
  189. Ibánez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P (2017)
    2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
    Rev Esp Cardiol (Engl Ed), 70 (12), 1082
    DOI 10.1016/j.rec.2017.11.010, PubMed 29198432
  190. Atar D, Hanssen KF (2017)
    Type 2 Diabetes and Heart Failure - More Scrutiny Wanted!
    Cardiology, 139 (1), 37-39
    DOI 10.1159/000484345, PubMed 29186706
  191. Agewall S (2017)
    European Heart Journal - Cardiovascular Pharmacotherapy: A fast growing baby-filling an important gap in the literature
    Eur Heart J, 38 (44), 3251
    DOI 10.1093/eurheartj/ehx619, PubMed 29177414
  192. Fakhri Y, Sejersten M, Schoos MM, Hansen HS, Dubois-Rande JL, Hall TS, Larsen AI, Jensen SE, Engblom H, Arheden H, Kastrup J, Atar D, Clemmensen P (2017)
    Electrocardiographic scores of severity and acuteness of myocardial ischemia predict myocardial salvage in patients with anterior ST-segment elevation myocardial infarction
    J Electrocardiol, 51 (2), 195-202
    DOI 10.1016/j.jelectrocard.2017.11.002, PubMed 29174706
  193. Kvakkestad KM, Sandvik L, Andersen GØ, Sunde K, Halvorsen S (2017)
    Long-term survival in patients with acute myocardial infarction and out-of-hospital cardiac arrest: A prospective cohort study
    Resuscitation, 122, 41-47
    DOI 10.1016/j.resuscitation.2017.11.047, PubMed 29155294
  194. Opstad TB, Seljeflot I, Bøhmer E, Arnesen H, Halvorsen S (2017)
    MMP-9 and Its Regulators TIMP-1 and EMMPRIN in Patients with Acute ST-Elevation Myocardial Infarction: A NORDISTEMI Substudy
    Cardiology, 139 (1), 17-24
    DOI 10.1159/000481684, PubMed 29141241
  195. Russo JJ, Goodman SG, Cantor WJ, Ko DT, Bagai A, Tan MK, Di Mario C, Halvorsen S, Le May M, Fernandez-Avilés F, Scheller B, Armstrong PW, Borgia F, Piscione F, Sanchez PL, Yan AT (2017)
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis
    Am Heart J, 193, 46-54
    DOI 10.1016/j.ahj.2017.07.015, PubMed 29129254
  196. Niessner A, Tamargo J, Koller L, Saely CH, Schmidt TA, Savarese G, Wassmann S, Rosano G, Ceconi C, Torp-Pedersen C, Kaski JC, Kjeldsen KP, Agewall S, Walther T, Drexel H, Lewis BS (2018)
    Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
    Eur Heart J, 39 (24), 2274-2281
    DOI 10.1093/eurheartj/ehx625, PubMed 29126266
  197. Graham I, Filippatos G, Atar D, Vardas PE, Pinto FJ, Fitzsimons D (2017)
    Patient engagement
    Eur Heart J, 38 (42), 3114-3115
    DOI 10.1093/eurheartj/ehx600, PubMed 29121227
  198. Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T (2017)
    Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study
    J Am Heart Assoc, 6 (11)
    DOI 10.1161/JAHA.117.006513, PubMed 29118031
  199. Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Storås TH, Ree AH, Gravdehaug B, Røsjø H, Steine K, Geisler J, Schulz-Menger J, Omland T (2018)
    Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial
    Eur Heart J Cardiovasc Imaging, 19 (5), 544-552
    DOI 10.1093/ehjci/jex159, PubMed 29106497
  200. Allencherril J, Fakhri Y, Engblom H, Heiberg E, Carlsson M, Dubois-Rande JL, Halvorsen S, Hall TS, Larsen AI, Jensen SE, Arheden H, Atar D, Clemmensen P, Shah DJ, Cheong B, Sejersten M, Birnbaum Y (2017)
    Appropriateness of anteroseptal myocardial infarction nomenclature evaluated by late gadolinium enhancement cardiovascular magnetic resonance imaging
    J Electrocardiol, 51 (2), 218-223
    DOI 10.1016/j.jelectrocard.2017.09.013, PubMed 29103621
  201. Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, Atar D, Wallentin L, Granger CB, Alexander JH, ARISTOTLE Investigators (2017)
    Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin
    Stroke, 48 (12), 3266-3273
    DOI 10.1161/STROKEAHA.117.017574, PubMed 29089455
  202. Deyab G, Hokstad I, Whist JE, Smastuen MC, Agewall S, Lyberg T, Ronda N, Mikkelsen K, Hjeltnes G, Hollan I (2017)
    Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis
    Arthritis Res Ther, 19 (1), 232
    DOI 10.1186/s13075-017-1439-1, PubMed 29041979
  203. Agewall S, Tjessem LH, Rossignol P, Zannad F, Atar D, Lamiral Z, Machu JL, Dickstein K, Kjekshus J, von Lueder TG, Girerd N, High Risk Myocardial Infarction Database Initiative investigators (2017)
    Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative
    Int J Cardiol, 249, 274-281
    DOI 10.1016/j.ijcard.2017.09.182, PubMed 28964557
  204. Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey RF, Vilahur G (2017)
    Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
    J Am Coll Cardiol, 70 (14), 1760-1776
    DOI 10.1016/j.jacc.2017.08.037, PubMed 28958334
  205. Ritschel V, Shetelig C, Seljeflot I, Limalanathan S, Hoffmann P, Halvorsen S, Arnesen H, Eritsland J, Andersen GØ (2017)
    Evaluation of circulating levels of CCN2/connective tissue growth factor in patients with ST-elevation myocardial infarction
    Sci Rep, 7 (1), 11945
    DOI 10.1038/s41598-017-12372-w, PubMed 28931920
  206. Sejersten M, Fakhri Y, Pape M, Jensen SE, Heiberg E, Engblom H, Hall TS, Atar D, Clemmensen P (2017)
    Myocardium at risk assessed by electrocardiographic scores and cardiovascular magnetic resonance - a MITOCARE substudy
    J Electrocardiol, 50 (6), 725-731
    DOI 10.1016/j.jelectrocard.2017.08.019, PubMed 28918213
  207. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, ESC Scientific Document Group (2018)
    2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
    Eur Heart J, 39 (2), 119-177
    DOI 10.1093/eurheartj/ehx393, PubMed 28886621
  208. Agewall S (2017)
    Morphine in acute heart failure
    J Thorac Dis, 9 (7), 1851-1854
    DOI 10.21037/jtd.2017.06.129, PubMed 28839982
  209. Campo G, Pavasini R, Morciano G, Lincoff MA, C Gibson M, Kitakaze M, Lonborg J, Ahluwalia A, Ishii H, Frenneaux M, Ovize M, Galvani M, Atar D, Ibanez B, Cerisano G, Biscaglia S, Neil BJ, Asakura M, Engstrom T, Jones DA, Dawson D, Ferrari R, Pinton P, Ottani F (2017)
    Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention
    Data Brief, 14, 197-205
    DOI 10.1016/j.dib.2017.07.033, PubMed 28795098
  210. von Lueder TG, Kotecha D, Atar D, Hopper I (2017)
    Neurohormonal Blockade in Heart Failure
    Card Fail Rev, 3 (1), 19-24
    DOI 10.15420/cfr.2016:22:2, PubMed 28785471
  211. Butt N, Bache-Mathiesen LK, Nordrehaug JE, Tuseth V, Munk PS, Bonarjee V, Hall TS, Jensen SE, Halvorsen S, Firat H, Atar D, Larsen AI (2017)
    Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins
    Cardiology, 138 (2), 122-132
    DOI 10.1159/000475460, PubMed 28651249
  212. Campo G, Pavasini R, Morciano G, Lincoff AM, Gibson CM, Kitakaze M, Lonborg J, Ahluwalia A, Ishii H, Frenneaux M, Ovize M, Galvani M, Atar D, Ibanez B, Cerisano G, Biscaglia S, Neil BJ, Asakura M, Engstrom T, Jones DA, Dawson D, Ferrari R, Pinton P, Ottani F (2017)
    Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials
    Int J Cardiol, 244, 59-66
    DOI 10.1016/j.ijcard.2017.06.040, PubMed 28634037
  213. Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED, TECOS Study Group (2017)
    Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)
    Circulation, 136 (13), 1193-1203
    DOI 10.1161/CIRCULATIONAHA.117.027252, PubMed 28626088
  214. Stubnova V, Os I, Grundtvig M, Atar D, Waldum-Grevbo B (2017)
    Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study
    Cardiorenal Med, 7 (2), 128-136
    DOI 10.1159/000454933, PubMed 28611786
  215. Shavadia J, Welsh R, Gershlick A, Zheng Y, Huber K, Halvorsen S, Steg PG, Van de Werf F, Armstrong PW (2016)
    Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study
    J Am Heart Assoc, 5 (6)
    DOI 10.1161/JAHA.116.003559, PubMed 28525886
  216. Fröhlich H, Henning F, Täger T, Schellberg D, Grundtvig M, Goode K, Corletto A, Kazmi S, Hole T, Katus HA, Atar D, Cleland JGF, Agewall S, Frankenstein L, Clark AL (2018)
    Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study
    Eur Heart J Cardiovasc Pharmacother, 4 (2), 82-92
    DOI 10.1093/ehjcvp/pvx013, PubMed 28475676
  217. Gulseth HL, Wium C, Angel K, Eriksen EF, Birkeland KI (2017)
    Effects of Vitamin D Supplementation on Insulin Sensitivity and Insulin Secretion in Subjects With Type 2 Diabetes and Vitamin D Deficiency: A Randomized Controlled Trial
    Diabetes Care, 40 (7), 872-878
    DOI 10.2337/dc16-2302, PubMed 28468770
  218. Fröhlich H, Torres L, Täger T, Schellberg D, Corletto A, Kazmi S, Goode K, Grundtvig M, Hole T, Katus HA, Cleland JGF, Atar D, Clark AL, Agewall S, Frankenstein L (2017)
    Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure
    Clin Res Cardiol, 106 (9), 711-721
    DOI 10.1007/s00392-017-1115-0, PubMed 28434020
  219. Lorenz MW, Abdi NA, Scheckenbach F, Pflug A, Bülbül A, Catapano AL, Agewall S, Ezhov M, Bots ML, Kiechl S, Orth A, PROG-IMT study group (2017)
    Automatic identification of variables in epidemiological datasets using logic regression
    BMC Med Inform Decis Mak, 17 (1), 40
    DOI 10.1186/s12911-017-0429-1, PubMed 28407816
  220. Fröhlich H, Raman N, Täger T, Schellberg D, Goode KM, Kazmi S, Grundtvig M, Hole T, Cleland JGF, Katus HA, Agewall S, Clark AL, Atar D, Frankenstein L (2017)
    Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure
    Int J Cardiol, 238, 97-104
    DOI 10.1016/j.ijcard.2017.03.028, PubMed 28342630
  221. Papp J, Zima E, Bover R, Karaliute R, Rossi A, Szymanski C, Troccoli R, Schneider J, Fagerland MW, Camm AJ, Atar D (2017)
    Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
    Eur Heart J Cardiovasc Pharmacother, 3 (3), 147-150
    DOI 10.1093/ehjcvp/pvx003, PubMed 28329309
  222. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, Ceconi C, Drexel H, Kjeldsen K, Savarese G, Torp-Pedersen C, Atar D, Lewis BS, Agewall S (2017)
    Gender differences in the effects of cardiovascular drugs
    Eur Heart J Cardiovasc Pharmacother, 3 (3), 163-182
    DOI 10.1093/ehjcvp/pvw042, PubMed 28329228
  223. Kvakkestad KM, Wang Fagerland M, Eritsland J, Halvorsen S (2017)
    Gender differences in all-cause, cardiovascular and cancer mortality during long-term follow-up after acute myocardial infarction; a prospective cohort study
    BMC Cardiovasc Disord, 17 (1), 75
    DOI 10.1186/s12872-017-0508-3, PubMed 28288586
  224. Sanders MF, van Doormaal PJ, Beeftink MMA, Bots ML, Fadl Elmula FEM, Habets J, Hammer F, Hoffmann P, Jacobs L, Mark PB, Persu A, Renkin J, Roditi G, Spiering W, Staessen JA, Taylor AH, Verloop WL, Vink EE, Vonken EJ, Voskuil M, Leiner T, Blankestijn PJ, European Network COordinating research on Renal Denervation (ENCOReD) Consortium (2017)
    Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography
    Eur Radiol, 27 (9), 3934-3941
    DOI 10.1007/s00330-017-4770-7, PubMed 28271154
  225. Shetelig C, Limalanathan S, Eritsland J, Hoffmann P, Seljeflot I, Gran JM, Aukrust P, Ueland T, Andersen GØ (2017)
    Osteoprotegerin levels in ST-elevation myocardial infarction: Temporal profile and association with myocardial injury and left ventricular function
    PLoS One, 12 (3), e0173034
    DOI 10.1371/journal.pone.0173034, PubMed 28253327
  226. Seemann F, Pahlm U, Steding-Ehrenborg K, Ostenfeld E, Erlinge D, Dubois-Rande JL, Jensen SE, Atar D, Arheden H, Carlsson M, Heiberg E (2017)
    Time-resolved tracking of the atrioventricular plane displacement in Cardiovascular Magnetic Resonance (CMR) images
    BMC Med Imaging, 17 (1), 19
    DOI 10.1186/s12880-017-0189-5, PubMed 28241751
  227. Deyab G, Hokstad I, Whist JE, Småstuen MC, Agewall S, Lyberg T, Bottazzi B, Meroni PL, Leone R, Hjeltnes G, Hollan I (2017)
    Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    PLoS One, 12 (2), e0169830
    DOI 10.1371/journal.pone.0169830, PubMed 28225768
  228. Brolin EB, Agewall S, Cederlund K, Ekenbäck C, Henareh L, Malmqvist K, Rück A, Svensson A, Tornvall P (2017)
    Plasma biomarker levels and non-obstructive coronary artery disease determined by coronary computed tomography angiography
    Clin Physiol Funct Imaging, 38 (2), 246-253
    DOI 10.1111/cpf.12407, PubMed 28168796
  229. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, De Caterina R, Zimarino M, Roffi M, Kjeldsen K, Atar D, Kaski JC, Sechtem U, Tornvall P, WG on Cardiovascular Pharmacotherapy (2017)
    ESC working group position paper on myocardial infarction with non-obstructive coronary arteries
    Eur Heart J, 38 (3), 143-153
    DOI 10.1093/eurheartj/ehw149, PubMed 28158518
  230. Rubboli A, Agewall S, Huber K, Lip GYH (2017)
    New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose
    Eur J Intern Med, 40, e11-e12
    DOI 10.1016/j.ejim.2017.01.003, PubMed 28087220
  231. Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H, Saely CH, Drexel H (2017)
    Comprehensive efforts to increase adherence to statin therapy
    Eur Heart J, 38 (32), 2473-2479
    DOI 10.1093/eurheartj/ehw628, PubMed 28077470
  232. Atar D (2017)
    European Heart Journal-Cardiovascular Pharmacotherapy in 2016: entering a new level of international recognition
    Eur Heart J Cardiovasc Pharmacother, 3 (1), 3-4
    DOI 10.1093/ehjcvp/pvw024, PubMed 28062654
  233. Agewall S (2017)
    Anticoagulation, atherosclerosis, and heart failure
    Eur Heart J Cardiovasc Pharmacother, 3 (1), 1-2
    DOI 10.1093/ehjcvp/pvw037, PubMed 28062653
  234. Fossum S, Vikanes ÅV, Naess Ø, Vos L, Grotmol T, Halvorsen S (2016)
    Hyperemesis gravidarum and long-term mortality: a population-based cohort study
    BJOG, 124 (7), 1080-1087
    DOI 10.1111/1471-0528.14454, PubMed 27981734
  235. Atar D, Benussi S, Kirchhof P (2016)
    'Ten Commandments' of 2016 ESC Guidelines for the management of atrial fibrillation
    Eur Heart J, 37 (38), 2853
    DOI 10.1093/eurheartj/ehw370, PubMed 27923817
  236. Chiva-Blanch G, Bratseth V, Ritschel V, Andersen GØ, Halvorsen S, Eritsland J, Arnesen H, Badimon L, Seljeflot I (2016)
    Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients
    Int J Cardiol, 227, 876-881
    DOI 10.1016/j.ijcard.2016.11.302, PubMed 27915085
  237. Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL, Weiss TW, Collet JP, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J, Verheugt FWA, Lanas A, Al-Shahi Salman R, Steg PG, Huber K, ESC Working Group on Thrombosis (2017)
    Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis
    Eur Heart J, 38 (19), 1455-1462
    DOI 10.1093/eurheartj/ehw454, PubMed 27789570
  238. Agewall S, Lewis BS, Atar D (2016)
    Cardiovascular pharmacotherapy
    Int J Cardiol, 224, 412-415
    DOI 10.1016/j.ijcard.2016.09.065, PubMed 27690338
  239. Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, Jonasson C (2016)
    A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
    Eur Heart J Cardiovasc Pharmacother, 3 (1), 28-36
    DOI 10.1093/ehjcvp/pvw031, PubMed 27680880
  240. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK, GARFIELD-AF Investigators (2016)
    Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
    Heart, 103 (4), 307-314
    DOI 10.1136/heartjnl-2016-309832, PubMed 27647168
  241. Agewall S (2016)
    The application to MEDLINE from European Heart Journal-Cardiovascular Pharmacotherapy has been accepted!
    Eur Heart J Cardiovasc Pharmacother, 2 (4), 207-8
    DOI 10.1093/ehjcvp/pvw021, PubMed 27600901
  242. Jortveit J, Govatsmark RE, Langørgen J, Hole T, Mannsverk J, Olsen S, Risøe C, Halvorsen S (2016)
    Gender differences in the assessment and treatment of myocardial infarction
    Tidsskr Nor Laegeforen, 136 (14-15), 1215-22
    DOI 10.4045/tidsskr.16.0224, PubMed 27554562
  243. Agewall S (2015)
    Cardiovascular Pharmacotherapy is moving!
    Eur Heart J Cardiovasc Pharmacother, 1 (3), 149
    DOI 10.1093/ehjcvp/pvv025, PubMed 27533986
  244. Ezekowitz JA, Lewis BS, Lopes RD, Wojdyla DM, McMurray JJ, Hanna M, Atar D, Cecilia Bahit M, Keltai M, Lopez-Sendon JL, Pais P, Ruzyllo W, Wallentin L, Granger CB, Alexander JH (2015)
    Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial
    Eur Heart J Cardiovasc Pharmacother, 1 (2), 86-94
    DOI 10.1093/ehjcvp/pvu024, PubMed 27533976
  245. Agewall S (2015)
    European Heart Journal - CVP: what is next?
    Eur Heart J Cardiovasc Pharmacother, 1 (2), 73
    DOI 10.1093/ehjcvp/pvv009, PubMed 27533970
  246. Atar D, Agewall S (2015)
    End of story? Studies on prevention of reperfusion injury encounter perpetual defeats
    Eur Heart J Cardiovasc Pharmacother, 1 (1), 46-7
    DOI 10.1093/ehjcvp/pvu018, PubMed 27533965
  247. De Blois J, Fagerland MW, Grundtvig M, Semb AG, Gullestad L, Westheim A, Hole T, Atar D, Agewall S (2015)
    ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry
    Eur Heart J Cardiovasc Pharmacother, 1 (1), 31-6
    DOI 10.1093/ehjcvp/pvu010, PubMed 27533962
  248. Agewall S (2015)
    European Heart Journal - Cardiovascular Pharmacotherapy: a new journal within the European Heart Journal family
    Eur Heart J Cardiovasc Pharmacother, 1 (1), 1
    DOI 10.1093/ehjcvp/pvu022, PubMed 27533955
  249. Agewall S (2016)
    News from EHJCVP
    Eur Heart J Cardiovasc Pharmacother, 2 (3), 141
    DOI 10.1093/ehjcvp/pvw010, PubMed 27533754
  250. Schmidt M, Lamberts M, Olsen AM, Fosbøll EL, Niessner A, Tamargo J, Rosano G, Agewall S, Kaski JC, Kjeldsen K, Lewis BS, Torp-Pedersen C (2016)
    Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology
    Eur Heart J Cardiovasc Pharmacother, 2 (2), 108-18
    DOI 10.1093/ehjcvp/pvv054, PubMed 27533522
  251. Agewall S (2016)
    Update from EHJ CVP
    Eur Heart J Cardiovasc Pharmacother, 2 (2), 77-8
    DOI 10.1093/ehjcvp/pvw004, PubMed 27533516
  252. Agewall S (2016)
    Second year of a journal
    Eur Heart J Cardiovasc Pharmacother, 2 (1), 1-2
    DOI 10.1093/ehjcvp/pvv049, PubMed 27533054
  253. Agewall S (2015)
    Starting up a new Journal within the European Heart Journal Family
    Eur Heart J Cardiovasc Pharmacother, 1 (4), 213
    DOI 10.1093/ehjcvp/pvv033, PubMed 27532442
  254. Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L, Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators (2016)
    Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial
    JAMA Cardiol, 1 (6), 673-81
    DOI 10.1001/jamacardio.2016.1829, PubMed 27463942
  255. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED, Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group (2016)
    Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial
    JAMA Cardiol, 1 (2), 126-35
    DOI 10.1001/jamacardio.2016.0103, PubMed 27437883
  256. Gresslien T, Agewall S (2016)
    Troponin and exercise
    Int J Cardiol, 221, 609-21
    DOI 10.1016/j.ijcard.2016.06.243, PubMed 27420587
  257. Ritschel VN, Seljeflot I, Arnesen H, Halvorsen S, Eritsland J, Fagerland MW, Andersen GØ (2016)
    Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction
    J Am Heart Assoc, 5 (6)
    DOI 10.1161/JAHA.115.003014, PubMed 27412895
  258. Nordlund D, Heiberg E, Carlsson M, Fründ ET, Hoffmann P, Koul S, Atar D, Aletras AH, Erlinge D, Engblom H, Arheden H (2016)
    Extent of Myocardium at Risk for Left Anterior Descending Artery, Right Coronary Artery, and Left Circumflex Artery Occlusion Depicted by Contrast-Enhanced Steady State Free Precession and T2-Weighted Short Tau Inversion Recovery Magnetic Resonance Imaging
    Circ Cardiovasc Imaging, 9 (7)
    DOI 10.1161/CIRCIMAGING.115.004376, PubMed 27412659
  259. Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Floch CL, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M et al. (2016)
    Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489]
    Eur J Heart Fail, 18 (6), 727
    DOI 10.1002/ejhf.591, PubMed 27324688
  260. Halvorsen S, Jortveit J, Hasvold P, Thuresson M, Øie E (2016)
    Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction
    BMC Cardiovasc Disord, 16, 115
    DOI 10.1186/s12872-016-0283-6, PubMed 27246583
  261. Engblom H, Tufvesson J, Jablonowski R, Carlsson M, Aletras AH, Hoffmann P, Jacquier A, Kober F, Metzler B, Erlinge D, Atar D, Arheden H, Heiberg E (2016)
    A new automatic algorithm for quantification of myocardial infarction imaged by late gadolinium enhancement cardiovascular magnetic resonance: experimental validation and comparison to expert delineations in multi-center, multi-vendor patient data
    J Cardiovasc Magn Reson, 18 (1), 27
    DOI 10.1186/s12968-016-0242-5, PubMed 27145749
  262. Graham JJ, Yan AT, Tan MK, Cantor WJ, DiMario C, Jolly SS, Halvorsen S, Fernandez-Aviles F, Le May MR, Scheller B, Borgia F, Piscione F, Madan M, Goodman SG (2016)
    Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials
    Cardiovasc Revasc Med, 17 (5), 295-301
    DOI 10.1016/j.carrev.2016.03.008, PubMed 27116940
  263. Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M et al. (2016)
    Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency
    Eur J Heart Fail, 18 (5), 482-9
    DOI 10.1002/ejhf.516, PubMed 27071916
  264. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L (2016)
    The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial
    Eur Heart J, 37 (38), 2869-2878
    DOI 10.1093/eurheartj/ehw124, PubMed 27071819
  265. Nordlund D, Klug G, Heiberg E, Koul S, Larsen TH, Hoffmann P, Metzler B, Erlinge D, Atar D, Aletras AH, Carlsson M, Engblom H, Arheden H (2016)
    Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction
    Eur Heart J Cardiovasc Imaging, 17 (7), 744-53
    DOI 10.1093/ehjci/jew027, PubMed 27002140
  266. Schmidt M, Lamberts M, Olsen AM, Fosbøll E, Niessner A, Tamargo J, Rosano G, Agewall S, Kaski JC, Kjeldsen K, Lewis BS, Torp-Pedersen C (2016)
    Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology
    Eur Heart J, 37 (13), 1015-23
    DOI 10.1093/eurheartj/ehv505, PubMed 26984863
  267. Engblom H, Heiberg E, Erlinge D, Jensen SE, Nordrehaug JE, Dubois-Randé JL, Halvorsen S, Hoffmann P, Koul S, Carlsson M, Atar D, Arheden H (2016)
    Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint
    J Am Heart Assoc, 5 (3), e002708
    DOI 10.1161/JAHA.115.002708, PubMed 26961520
  268. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Collet JP, Halvorsen S, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Ricci F, Sibbing D, Siegbahn A, Storey RF, Ten Berg J, Verheugt FW, Weitz JI (2016)
    Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease
    Thromb Haemost, 115 (4), 685-711
    DOI 10.1160/TH15-09-0703, PubMed 26952877
  269. von Lueder TG, Hopper I, Kotecha D, Atar D (2016)
    In memoriam Henry Krum, 1958-2015
    Cardiology, 134 (2), 107-8
    DOI 10.1159/000444294, PubMed 26950607
  270. Tufvesson J, Carlsson M, Aletras AH, Engblom H, Deux JF, Koul S, Sörensson P, Pernow J, Atar D, Erlinge D, Arheden H, Heiberg E (2016)
    Automatic segmentation of myocardium at risk from contrast enhanced SSFP CMR: validation against expert readers and SPECT
    BMC Med Imaging, 16, 19
    DOI 10.1186/s12880-016-0124-1, PubMed 26946139
  271. Hilde JM, Skjørten I, Hansteen V, Melsom MN, Atar D, Hisdal J, Humerfelt S, Steine K (2016)
    Assessment of Right Ventricular Afterload in COPD
    COPD, 13 (2), 176-85
    DOI 10.3109/15412555.2015.1057275, PubMed 26914261
  272. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T (2016)
    Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
    Eur Heart J, 37 (21), 1671-80
    DOI 10.1093/eurheartj/ehw022, PubMed 26903532
  273. Bainey KR, Fresco C, Zheng Y, Halvorsen S, Carvalho A, Ostojic M, Goldstein P, Gershlick AH, Westerhout CM, Van de Werf F, Armstrong PW, STREAM Investigators (2016)
    Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction
    Heart, 102 (7), 527-33
    DOI 10.1136/heartjnl-2015-308075, PubMed 26783237
  274. Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators (2015)
    Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
    J Am Heart Assoc, 4 (12)
    DOI 10.1161/JAHA.115.002015, PubMed 26627878
  275. Atar D, Agewall S (2015)
    Morphine in myocardial infarction: balancing on the tight rope
    Eur Heart J, 37 (3), 253-5
    DOI 10.1093/eurheartj/ehv546, PubMed 26491111
  276. Ellingsrud C, Agewall S (2015)
    Morphine in the treatment of acute pulmonary oedema--Why?
    Int J Cardiol, 202, 870-3
    DOI 10.1016/j.ijcard.2015.10.014, PubMed 26476045
  277. Steffel J, Atar D (2015)
    Non-vitamin K oral anticoagulants in 'valvular' atrial fibrillation: a call for action
    Europace, 18 (1), 1-3
    DOI 10.1093/europace/euv318, PubMed 26462701
  278. von Lueder TG, Girerd N, Atar D, Agewall S, Lamiral Z, Kanbay M, Pitt B, Dickstein K, Zannad F, Rossignol P, High-Risk Myocardial Infarction Database Initiative Investigators (2015)
    Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative
    Eur J Heart Fail, 17 (11), 1144-51
    DOI 10.1002/ejhf.419, PubMed 26424212
  279. Hansen CH, Ritschel V, Halvorsen S, Andersen GØ, Bjørnerheim R, Eritsland J, Arnesen H, Seljeflot I (2015)
    Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction
    Thromb J, 13, 31
    DOI 10.1186/s12959-015-0061-1, PubMed 26396552
  280. Lindholm D, Storey RF, Christersson C, Halvorsen S, Grove EL, Braun OÖ, Varenhorst C, James SK (2015)
    Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr
    Am Heart J, 170 (3), 465-70
    DOI 10.1016/j.ahj.2015.06.014, PubMed 26385029
  281. Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Mărgulescu AD, Wallentin L, Atar D (2015)
    Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial
    Eur Heart J, 36 (46), 3268-75
    DOI 10.1093/eurheartj/ehv447, PubMed 26371113
  282. Shavadia J, Zheng Y, Dianati Maleki N, Huber K, Halvorsen S, Goldstein P, Gershlick AH, Wilcox R, Van de Werf F, Armstrong PW (2015)
    Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction?
    J Am Heart Assoc, 4 (8), e002049
    DOI 10.1161/JAHA.115.002049, PubMed 26304934
  283. Fröhlich H, Zhao J, Täger T, Cebola R, Schellberg D, Katus HA, Grundtvig M, Hole T, Atar D, Agewall S, Frankenstein L (2015)
    Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study
    Circ Heart Fail, 8 (5), 887-96
    DOI 10.1161/CIRCHEARTFAILURE.114.001701, PubMed 26175538
  284. Abdel-Qadir H, Yan AT, Tan M, Borgia F, Piscione F, Di Mario C, Halvorsen S, Cantor WJ, Westerhout CM, Scheller B, Le May MR, Fernandez-Aviles F, Sánchez PL, Lee DS, Goodman SG (2015)
    Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis
    Heart, 101 (19), 1554-61
    DOI 10.1136/heartjnl-2015-307815, PubMed 26175478
  285. Andreotti F, Rocca B, Husted S, Ajjan RA, ten Berg J, Cattaneo M, Collet JP, De Caterina R, Fox KA, Halvorsen S, Huber K, Hylek EM, Lip GY, Montalescot G, Morais J, Patrono C, Verheugt FW, Wallentin L, Weiss TW, Storey RF, ESC Thrombosis Working Group (2015)
    Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
    Eur Heart J, 36 (46), 3238-49
    DOI 10.1093/eurheartj/ehv304, PubMed 26163482
  286. Brolin EB, Agewall S, Brismar TB, Caidahl K, Tornvall P, Cederlund K (2015)
    Neither endothelial function nor carotid artery intima-media thickness predicts coronary computed tomography angiography plaque burden in clinically healthy subjects: a cross-sectional study
    BMC Cardiovasc Disord, 15, 63
    DOI 10.1186/s12872-015-0061-x, PubMed 26148508
  287. Hollan I, Dessein PH, Ronda N, Wasko MC, Svenungsson E, Agewall S, Cohen-Tervaert JW, Maki-Petaja K, Grundtvig M, Karpouzas GA, Meroni PL (2015)
    Prevention of cardiovascular disease in rheumatoid arthritis
    Autoimmun Rev, 14 (10), 952-69
    DOI 10.1016/j.autrev.2015.06.004, PubMed 26117596
  288. Khan R, Lopes RD, Neely ML, Stevens SR, Harrington RA, Diaz R, Cools F, Jansky P, Montalescot G, Atar D, Lopez-Sendon J, Flather M, Liaw D, Wallentin L, Alexander JH, Goodman SG, Apixaban for Prevention of Acute Ischemic Safety Events (APPRAISE)-2 Steering Committee and Investigators (2015)
    Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome
    Heart, 101 (18), 1475-84
    DOI 10.1136/heartjnl-2014-307346, PubMed 26109589
  289. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, Gulizia M, Halvorsen S, Hindricks G, Kuck KH, Moya A, Potpara T, Roldan V, Tilz R, Lip GY (2015)
    Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)
    Europace, 17 (8), 1197-214
    DOI 10.1093/europace/euv190, PubMed 26105732
  290. Rubboli A, Agewall S, Huber K, Lip GY (2015)
    New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint
    Int J Cardiol, 196, 133-8
    DOI 10.1016/j.ijcard.2015.06.006, PubMed 26093527
  291. Jackson N, Atar D, Borentain M, Breithardt G, van Eickels M, Endres M, Fraass U, Friede T, Hannachi H, Janmohamed S, Kreuzer J, Landray M, Lautsch D, Le Floch C, Mol P, Naci H, Samani NJ, Svensson A, Thorstensen C, Tijssen J, Vandzhura V, Zalewski A, Kirchhof P (2015)
    Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology
    Eur Heart J, 37 (9), 747-54
    DOI 10.1093/eurheartj/ehv213, PubMed 26077039
  292. Atar D (2015)
    The National Cardiac Societies of the European Society of Cardiology
    Eur Heart J, 36 (21), 1278
    DOI 10.1093/eurheartj/ehv091, PubMed 26034059
  293. Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W (2015)
    Atherosclerosis: Recent trials, new targets and future directions
    Int J Cardiol, 192, 72-81
    DOI 10.1016/j.ijcard.2015.05.013, PubMed 26002254
  294. De Blois J, Kjellstrom T, Agewall S, Ezekowitz JA, Armstrong PW, Atar D (2015)
    The Effects of Climate Change on Cardiac Health
    Cardiology, 131 (4), 209-17
    DOI 10.1159/000398787, PubMed 25997478
  295. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, Camm AJ, Antman EM, Ruff CT (2015)
    Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
    Eur Heart J, 36 (33), 2239-45
    DOI 10.1093/eurheartj/ehv201, PubMed 25971288
  296. Tornvall P, Gerbaud E, Behaghel A, Chopard R, Collste O, Laraudogoitia E, Leurent G, Meneveau N, Montaudon M, Perez-David E, Sörensson P, Agewall S (2015)
    Myocarditis or "true" infarction by cardiac magnetic resonance in patients with a clinical diagnosis of myocardial infarction without obstructive coronary disease: A meta-analysis of individual patient data
    Atherosclerosis, 241 (1), 87-91
    DOI 10.1016/j.atherosclerosis.2015.04.816, PubMed 25967935
  297. Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J (2015)
    Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC
    Eur Heart J, 36 (40), 2677-80
    DOI 10.1093/eurheartj/ehv161, PubMed 25948737
  298. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M (2015)
    Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis
    Ann Intern Med, 163 (1), 40-51
    DOI 10.7326/M14-2957, PubMed 25915661
  299. Agewall S (2015)
    How to save six million people per year
    Atherosclerosis, 240 (2), 387-8
    DOI 10.1016/j.atherosclerosis.2015.04.006, PubMed 25881201
  300. Bethke A, Halvorsen S, Bøhmer E, Abdelnoor M, Arnesen H, Hoffmann P (2015)
    Myocardial perfusion grade predicts final infarct size and left ventricular function in patients with ST-elevation myocardial infarction treated with a pharmaco-invasive strategy (thrombolysis and early angioplasty)
    EuroIntervention, 11 (5), 518-24
    DOI 10.4244/EIJY15M04_02, PubMed 25868877
  301. Wang BH, von Lueder TG, Kompa AR, Huang L, Webb R, Jordaan P, Atar D, Krum H (2015)
    Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis
    Int J Cardiol, 186, 104-5
    DOI 10.1016/j.ijcard.2015.03.116, PubMed 25828104
  302. Hodt A, Hisdal J, Stugaard M, Stranden E, Atar D, Steine K (2015)
    Increased LV apical untwist during preload reduction in healthy humans: an echocardiographic speckle tracking study during lower body negative pressure
    Physiol Rep, 3 (3)
    DOI 10.14814/phy2.12330, PubMed 25802362
  303. Kvakkestad KM, Abdelnoor M, Claussen PA, Eritsland J, Fossum E, Halvorsen S (2015)
    Long-term survival in octogenarians and older patients with ST-elevation myocardial infarction in the era of primary angioplasty: A prospective cohort study
    Eur Heart J Acute Cardiovasc Care, 5 (3), 243-52
    DOI 10.1177/2048872615574706, PubMed 25753053
  304. Gershlick AH, Westerhout CM, Armstrong PW, Huber K, Halvorsen S, Steg PG, Ostojic M, Goldstein P, Carvalho AC, Van de Werf F, Wilcox RG (2015)
    Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged
    Heart, 101 (9), 692-8
    DOI 10.1136/heartjnl-2014-306686, PubMed 25691510
  305. Mueller C, Auer J, Halvorsen S (2015)
    Cardiac troponin elevations in acute non-coronary disease: Helpful or not?
    Eur Heart J Acute Cardiovasc Care, 4 (5), 429-30
    DOI 10.1177/2048872615573921, PubMed 25678669
  306. Hall TS, Hallén J, Krucoff MW, Roe MT, Brennan DM, Agewall S, Atar D, Lincoff AM (2014)
    Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
    Am Heart J, 169 (2), 257-265.e1
    DOI 10.1016/j.ahj.2014.10.015, PubMed 25641535
  307. Madan M, Halvorsen S, Di Mario C, Tan M, Westerhout CM, Cantor WJ, Le May MR, Borgia F, Piscione F, Scheller B, Armstrong PW, Fernandez-Aviles F, Sanchez PL, Graham JJ, Yan AT, Goodman SG (2014)
    Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials
    JACC Cardiovasc Interv, 8 (1 Pt B), 166-174
    DOI 10.1016/j.jcin.2014.09.005, PubMed 25616922
  308. Sveen KA, Dahl-Jørgensen K, Stensaeth KH, Angel K, Seljeflot I, Sell DR, Monnier VM, Hanssen KF (2014)
    Glucosepane and oxidative markers in skin collagen correlate with intima media thickness and arterial stiffness in long-term type 1 diabetes
    J Diabetes Complications, 29 (3), 407-12
    DOI 10.1016/j.jdiacomp.2014.12.011, PubMed 25600701
  309. Claussen PA, Abdelnoor M, Kvakkestad KM, Eritsland J, Halvorsen S (2014)
    Prevalence of risk factors at presentation and early mortality in patients aged 80 years or older with ST-segment elevation myocardial infarction
    Vasc Health Risk Manag, 10, 683-9
    DOI 10.2147/VHRM.S72764, PubMed 25525366
  310. Ellingsrud C, Agewall S (2014)
    [Morphine in the treatment of acute pulmonary oedema]
    Tidsskr Nor Laegeforen, 134 (23-24), 2272-5
    DOI 10.4045/tidsskr.14.0359, PubMed 25492336
  311. Das D, Bakal JA, Westerhout CM, Hernandez AF, O'Connor CM, Atar D, McMurray JJ, Armstrong PW, Ezekowitz JA (2014)
    The association between meteorological events and acute heart failure: new insights from ASCEND-HF
    Int J Cardiol, 177 (3), 819-24
    DOI 10.1016/j.ijcard.2014.11.066, PubMed 25465826
  312. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B, O'Connor CM (2014)
    Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction
    J Am Coll Cardiol, 64 (21), 2281-93
    DOI 10.1016/j.jacc.2014.08.036, PubMed 25456761
  313. Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L (2014)
    Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy
    Clin Chem, 61 (2), 368-78
    DOI 10.1373/clinchem.2014.226936, PubMed 25451868
  314. Bagai A, Tan M, Di Mario C, Halvorsen S, Cantor WJ, Le May MR, Fernandez-Aviles F, Scheller B, Armstrong PW, Borgia F, Piscione F, Sánchez PL, Westerhout CM, Goodman SG, Yan AT (2014)
    Routine invasive management early after fibrinolysis: relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials
    Am Heart J, 168 (5), 757-65
    DOI 10.1016/j.ahj.2014.07.027, PubMed 25440805
  315. Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empana JP, Etgen T, Franco OH, Iglseder B, Johnsen SH, Kavousi M, Lind L, Liu J, Mathiesen EB, Norata GD, Olsen MH, Papagianni A, Poppert H, Price JF, Sacco RL, Yanez DN, Zhao D et al. (2014)
    Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration
    Eur J Prev Cardiol, 23 (2), 194-205
    DOI 10.1177/2047487314560664, PubMed 25416041
  316. von Lueder TG, Wang BH, Kompa AR, Huang L, Webb R, Jordaan P, Atar D, Krum H (2014)
    Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy
    Circ Heart Fail, 8 (1), 71-8
    DOI 10.1161/CIRCHEARTFAILURE.114.001785, PubMed 25362207
  317. Jortveit J, Govatsmark RE, Digre TA, Risøe C, Hole T, Mannsverk J, Slørdahl SA, Halvorsen S (2014)
    Myocardial infarction in Norway in 2013
    Tidsskr Nor Laegeforen, 134 (19), 1841-6
    DOI 10.4045/tidsskr.14.0804, PubMed 25314984
  318. van Kranenburg M, Magro M, Thiele H, de Waha S, Eitel I, Cochet A, Cottin Y, Atar D, Buser P, Wu E, Lee D, Bodi V, Klug G, Metzler B, Delewi R, Bernhardt P, Rottbauer W, Boersma E, Zijlstra F, van Geuns RJ (2014)
    Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients
    JACC Cardiovasc Imaging, 7 (9), 930-9
    DOI 10.1016/j.jcmg.2014.05.010, PubMed 25212799
  319. Kristiansen A, Brandt L, Agoritsas T, Akl EA, Berge E, Flem Jacobsen A, Granan LP, Halvorsen S, Guyatt G, Vandvik PO (2014)
    Applying new strategies for the national adaptation, updating, and dissemination of trustworthy guidelines: results from the Norwegian adaptation of the Antithrombotic Therapy and the Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Chest, 146 (3), 735-761
    DOI 10.1378/chest.13-2993, PubMed 25180724
  320. Kristiansen A, Brandt L, Agoritsas T, Akl EA, Berge E, Bondi J, Dahm AE, Granan LP, Halvorsen S, Holme PA, Flem Jacobsen A, Jacobsen EM, Neumann I, Sandset PM, Sætre T, Tveit A, Vartdal T, Guyatt G, Vandvik PO (2014)
    Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process
    Chest, 146 (3), 727-734
    DOI 10.1378/chest.13-2828, PubMed 25180723
  321. Atar D, Arheden H, Berdeaux A, Bonnet JL, Carlsson M, Clemmensen P, Cuvier V, Danchin N, Dubois-Randé JL, Engblom H, Erlinge D, Firat H, Halvorsen S, Hansen HS, Hauke W, Heiberg E, Koul S, Larsen AI, Le Corvoisier P, Nordrehaug JE, Paganelli F, Pruss RM, Rousseau H, Schaller S, Sonou G et al. (2014)
    Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results
    Eur Heart J, 36 (2), 112-9
    DOI 10.1093/eurheartj/ehu331, PubMed 25179768
  322. Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F, STREAM investigators (2014)
    ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up
    Circulation, 130 (14), 1139-45
    DOI 10.1161/CIRCULATIONAHA.114.009570, PubMed 25161043
  323. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document Reviewers, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J et al. (2014)
    Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)
    Eur Heart J, 35 (45), 3155-79
    DOI 10.1093/eurheartj/ehu298, PubMed 25154388
  324. Omland T, Røsjø H, Giannitsis E, Agewall S (2014)
    Troponins in heart failure
    Clin Chim Acta, 443, 78-84
    DOI 10.1016/j.cca.2014.08.016, PubMed 25151947
  325. Lip GY, Laroche C, Boriani G, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJ, Simantirakis E, Atar D, Maggioni AP, Tavazzi L (2014)
    Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry
    Europace, 17 (2), 194-206
    DOI 10.1093/europace/euu201, PubMed 25149078
  326. Kjeldsen SE, Sørensen H, Fadl Elmula FE, Brekke M, Gjønnæss E, Hjørnholm U, Kjære VN, Rostrup M, Fossum E, Os I, Stenehjem A, Høieggen A, Hoffmann P (2014)
    [Re: Renal sympathetic denervation in treatment-resistant hypertension]
    Tidsskr Nor Laegeforen, 134 (15), 1449-50
    DOI 10.4045/tidsskr.14.0931, PubMed 25138398
  327. Halvorsen S, Andreotti F, ten Berg JM, Cattaneo M, Coccheri S, Marchioli R, Morais J, Verheugt FW, De Caterina R (2014)
    Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis
    J Am Coll Cardiol, 64 (3), 319-27
    DOI 10.1016/j.jacc.2014.03.049, PubMed 25034070
  328. Njerve IU, Solheim S, Lunde K, Hoffmann P, Arnesen H, Seljeflot I (2014)
    Fractalkine levels are elevated early after PCI-treated ST-elevation myocardial infarction; no influence of autologous bone marrow derived stem cell injection
    Cytokine, 69 (1), 131-5
    DOI 10.1016/j.cyto.2014.05.022, PubMed 24930044
  329. Anker SD, Agewall S, Borggrefe M, Calvert M, Jaime Caro J, Cowie MR, Ford I, Paty JA, Riley JP, Swedberg K, Tavazzi L, Wiklund I, Kirchhof P (2014)
    The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials
    Eur Heart J, 35 (30), 2001-9
    DOI 10.1093/eurheartj/ehu205, PubMed 24904027
  330. Hall TS, Herrscher TE, Jarolim P, Fagerland MW, Jensen T, Agewall S, Atar D, Hallén J (2014)
    Myeloid-related protein-8/14 and C-reactive protein in individuals evaluated for obstructive sleep apnea
    Sleep Med, 15 (7), 762-8
    DOI 10.1016/j.sleep.2014.03.008, PubMed 24841106
  331. von Lueder TG, Atar D, Krum H (2014)
    Current role of neprilysin inhibitors in hypertension and heart failure
    Pharmacol Ther, 144 (1), 41-9
    DOI 10.1016/j.pharmthera.2014.05.002, PubMed 24836726
  332. Bøhmer E, Kristiansen IS, Arnesen H, Halvorsen S (2014)
    Health-related quality of life after myocardial infarction, does choice of method make a difference?
    Scand Cardiovasc J, 48 (4), 216-22
    DOI 10.3109/14017431.2014.923581, PubMed 24828790
  333. Lincoff AM, Roe M, Aylward P, Galla J, Rynkiewicz A, Guetta V, Zelizko M, Kleiman N, White H, McErlean E, Erlinge D, Laine M, Dos Santos Ferreira JM, Goodman S, Mehta S, Atar D, Suryapranata H, Jensen SE, Forster T, Fernandez-Ortiz A, Schoors D, Radke P, Belli G, Brennan D, Bell G et al. (2014)
    Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial
    Eur Heart J, 35 (37), 2516-23
    DOI 10.1093/eurheartj/ehu177, PubMed 24796339
  334. Limalanathan S, Andersen GØ, Kløw NE, Abdelnoor M, Hoffmann P, Eritsland J (2014)
    Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial
    J Am Heart Assoc, 3 (2), e000679
    DOI 10.1161/JAHA.113.000679, PubMed 24760962
  335. Helseth R, Solheim S, Opstad T, Hoffmann P, Arnesen H, Seljeflot I (2014)
    The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention
    Mediators Inflamm, 2014, 608414
    DOI 10.1155/2014/608414, PubMed 24737925
  336. Agewall S (2014)
    [Final reply: follow the Danish example]
    Lakartidningen, 111 (9-10), 405
    PubMed 24707558
  337. Ritschel VN, Seljeflot I, Arnesen H, Halvorsen S, Weiss T, Eritsland J, Andersen GØ (2013)
    IL-6 signalling in patients with acute ST-elevation myocardial infarction
    Results Immunol, 4, 8-13
    DOI 10.1016/j.rinim.2013.11.002, PubMed 24707455
  338. von Lueder TG, Atar D (2014)
    Comorbidities and polypharmacy
    Heart Fail Clin, 10 (2), 367-72
    DOI 10.1016/j.hfc.2013.12.001, PubMed 24656112
  339. Radke PW, Halvorsen S, Jukema JW, Kolh P, Annemans L, Postma MJ, Ardissino D, Kristensen SD, Bassand JP, Collet JP, Morais J, Tuñón J, Halcox J (2014)
    Networks for improving care in patients with acute coronary syndrome: A framework
    Acute Card Care, 16 (2), 41-8
    DOI 10.3109/17482941.2014.881502, PubMed 24654609
  340. Agewall S (2014)
    [Why all these guidelines?]
    Lakartidningen, 111 (5), 129
    PubMed 24624760
  341. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Høieggen A (2014)
    Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension
    Hypertension, 63 (5), 991-9
    DOI 10.1161/HYPERTENSIONAHA.114.03246, PubMed 24591332
  342. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L (2014)
    Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
    Eur Heart J, 35 (28), 1864-72
    DOI 10.1093/eurheartj/ehu046, PubMed 24561548
  343. Atar D, Bode C, Stuerzenbecher A, Verheugt FW (2014)
    Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade
    Fundam Clin Pharmacol, 28 (4), 353-63
    DOI 10.1111/fcp.12063, PubMed 24494730
  344. Johnson J, Manouras A, Bergholm F, Brodin LÅ, Agewall S, Henareh L (2013)
    The early diastolic myocardial velocity: a marker of increased risk in patients with coronary heart disease
    Clin Physiol Funct Imaging, 34 (5), 389-96
    DOI 10.1111/cpf.12110, PubMed 24438358
  345. Sørensen H, Fadl Elmula FE, Kjeldsen SE, Brekke M, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Fossum E, Os I, Stenehjem A, Høieggen A, Hoffmann P (2014)
    [Renal sympathetic denervation in treatment-resistant hypertension]
    Tidsskr Nor Laegeforen, 134 (1), 32-6
    DOI 10.4045/tidsskr.13.0276, PubMed 24429753
  346. Agewall S, Giannitsis E (2014)
    "Troponin elevation in coronary ischemia and necrosis"
    Curr Atheroscler Rep, 16 (3), 396
    DOI 10.1007/s11883-013-0396-7, PubMed 24425063
  347. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJ, Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP (2013)
    A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry
    Europace, 16 (3), 308-19
    DOI 10.1093/europace/eut373, PubMed 24351881
  348. Crisby M, Henareh L, Agewall S (2013)
    Relationship between oxidized LDL, IgM, and IgG autoantibodies to ox-LDL levels with recurrent cardiovascular events in Swedish patients with previous myocardial infarction
    Angiology, 65 (10), 932-6
    DOI 10.1177/0003319713512720, PubMed 24288363
  349. Jogestrand T, Agewall S, Gustafsson T, Henareh L (2013)
    Conventional treatment after myocardial infarction in routine clinical practice results in regression of left common carotid intima-media thickness
    Clin Physiol Funct Imaging, 34 (4), 322-6
    DOI 10.1111/cpf.12101, PubMed 24237780
  350. Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L, ARISTOTLE Investigators (2013)
    High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
    Circulation, 129 (6), 625-34
    DOI 10.1161/CIRCULATIONAHA.113.006286, PubMed 24226808
  351. Catalano M, Poredos P, Brodmann M, Wautrecht JC, Carpentier P, Roztocil K, Nikol S, Diamantopoulos E, Pecsvarady Z, Carlizza A, Sieron A, Stanek A, Olinic D, Stvrtinova V, Kozak M, Agewall S, Gallino A, Jaeger KA, Fitzgerald P, Colgan MP (2013)
    Requirements for angiology/vascular medicine
    Int Angiol, 32 (6), 608-12
    PubMed 24212296
  352. Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, Goto S, Hanna M, Huber K, Husted S, Lewis BS, McMurray JJ, Pais P, Pouleur H, Steg PG, Verheugt FW, Wojdyla DM, Granger CB, Wallentin L (2013)
    Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
    Eur Heart J, 35 (4), 224-32
    DOI 10.1093/eurheartj/eht445, PubMed 24144788
  353. Halvorsen S, Huber K (2013)
    Fibrinolytic treatment of ST-elevation myocardial infarction. Update 2014
    Hamostaseologie, 34 (1), 47-53
    DOI 10.5482/HAMO-13-07-0040, PubMed 24085113
  354. Ghanima W, Atar D, Sandset PM (2013)
    New oral anticoagulants--a review
    Tidsskr Nor Laegeforen, 133 (18), 1940-5
    DOI 10.4045/tidsskr.12.1111, PubMed 24084970
  355. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB, ARISTOTLE Investigators (2013)
    High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin
    J Am Coll Cardiol, 63 (1), 52-61
    DOI 10.1016/j.jacc.2013.07.093, PubMed 24055845
  356. Hall TS, Herrscher T, Jarolim P, Fagerland MW, Jensen T, Hallén J, Agewall S, Atar D (2013)
    Obstructive sleep apnea: no independent association to troponins
    Sleep Breath, 18 (2), 351-8
    DOI 10.1007/s11325-013-0892-6, PubMed 24043484
  357. Gulati G, Heck SL, Ree AH, Gravdehaug B, Røsjø H, Steine K, Bratland Å, Hoffmann P, Geisler J, Omland T (2013)
    [Cardioprotective treatment during adjuvant cancer therapy]
    Tidsskr Nor Laegeforen, 133 (17), 1832-6
    DOI 10.4045/tidsskr.12.1514, PubMed 24042297
  358. Namtvedt SK, Hisdal J, Randby A, Agewall S, Røsjø H, Omland T (2013)
    The author’s reply
    Heart, 100 (1), 81-2
    DOI 10.1136/heartjnl-2013-304648, PubMed 24014283
  359. Limalanathan S, Eritsland J, Andersen GØ, Kløw NE, Abdelnoor M, Hoffmann P (2013)
    Myocardial salvage is reduced in primary PCI-treated STEMI patients with microvascular obstruction, demonstrated by early and late CMR
    PLoS One, 8 (8), e71780
    DOI 10.1371/journal.pone.0071780, PubMed 23977143
  360. Aamodt AH, Sandset PM, Atar D, Tveit A, Russell D (2013)
    [Atrial fibrillation and stroke]
    Tidsskr Nor Laegeforen, 133 (14), 1453-7
    DOI 10.4045/tidsskr.12.0850, PubMed 23929293
  361. von Lueder TG, Atar D, Krum H (2013)
    Diuretic use in heart failure and outcomes
    Clin Pharmacol Ther, 94 (4), 490-8
    DOI 10.1038/clpt.2013.140, PubMed 23852396
  362. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Kjeldsen SE, Os I, Stenehjem AE, Høieggen A (2013)
    Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure
    Hypertension, 62 (3), 526-32
    DOI 10.1161/HYPERTENSIONAHA.113.01452, PubMed 23836798
  363. Kuliczkowski W, Urbaniak J, Hallén J, Woźniak M, Poloński L, Mysiak A, Atar D, Zembala M, Serebruany V (2013)
    Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty
    Kardiol Pol, 71 (5), 453-63
    DOI 10.5603/KP.2013.0091, PubMed 23788085
  364. Frankenstein L, Katus HA, Grundtvig M, Hole T, de Blois J, Schellberg D, Atar D, Zugck C, Agewall S, Norwegian Heart Failure Registry steering committee (2013)
    Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study
    Eur J Clin Pharmacol, 69 (10), 1747-55
    DOI 10.1007/s00228-013-1512-x, PubMed 23743778
  365. Agewall S (2013)
    Sick leave and a smoking ban
    Eur Heart J, 35 (5), 266-7
    DOI 10.1093/eurheartj/eht178, PubMed 23739243
  366. Serebruany VL, Pokov AN, Aradi D, Can M, DiNicolantonio J, Kipshidze N, Atar D (2014)
    Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial
    Am J Ther, 21 (6), 482-90
    DOI 10.1097/MJT.0b013e31826915ab, PubMed 23698186
  367. von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC, Krum H (2013)
    Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure
    Circ Heart Fail, 6 (3), 594-605
    DOI 10.1161/CIRCHEARTFAILURE.112.000289, PubMed 23694773
  368. Serebruany V, Atar D (2013)
    Prasugrel: the real-life perspective
    Circ Cardiovasc Qual Outcomes, 6 (3), 253-4
    DOI 10.1161/CIRCOUTCOMES.113.000239, PubMed 23674315
  369. Serebruany VL, Kipshidze N, Pershukov IV, Kuliczkowski W, Carnes J, Atar D (2014)
    Fatal sepsis and systemic inflammatory response syndrome after off-label prasugrel: a case report
    Am J Ther, 21 (6), e229-33
    DOI 10.1097/MJT.0b013e31828fdb1c, PubMed 23665886
  370. Hisdal J, Agewall S, Omland T (2013)
    Impaired endothelial function in persons with obstructive sleep apnoea: impact of obesity—the response
    Heart, 99 (13), 969
    DOI 10.1136/heartjnl-2013-303771, PubMed 23661637
  371. Agewall S (2013)
    [New European guidelines for acute and chronic heart failure]
    Lakartidningen, 110 (13-14), 672-3
    PubMed 23634620
  372. Ghanavatian S, Diep LM, Bárány P, Heimbürger O, Seeberger A, Stenvinkel P, Rohani M, Agewall S (2013)
    Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4
    Angiology, 65 (5), 443-9
    DOI 10.1177/0003319713483000, PubMed 23567479
  373. Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S, Lotan C (2013)
    Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?
    Eur Heart J, 34 (22), 1630-5
    DOI 10.1093/eurheartj/eht110, PubMed 23554440
  374. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F, STREAM Investigative Team (2013)
    Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction
    N Engl J Med, 368 (15), 1379-87
    DOI 10.1056/NEJMoa1301092, PubMed 23473396
  375. Hjeltnes G, Hollan I, Førre O, Wiik A, Lyberg T, Mikkelsen K, Agewall S (2013)
    Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor
    Clin Exp Rheumatol, 31 (3), 415-21
    PubMed 23465067
  376. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P (2013)
    Questionable levels of evidence in new atrial fibrillation guidelines? Reply
    Europace, 15 (3), 461-2
    DOI 10.1093/europace/eus394, PubMed 23430753
  377. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P (2013)
    'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply
    Europace, 15 (3), 460-1
    DOI 10.1093/europace/eus386, PubMed 23430752
  378. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF, ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis (2013)
    Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
    Eur Heart J, 34 (23), 1708-13, 1713a-1713b
    DOI 10.1093/eurheartj/eht042, PubMed 23425521
  379. Verheugt FW, Clemmensen P, Mehran R, Agewall S, Pocock SJ, Goldstein S, Torp-Pedersen C, Simoons ML, Borer JS, Khder YM, Burton P, Deliargyris E, McMurray JJ, Berkowitz SD, Stough WG, Zannad F (2013)
    Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy
    Eur Heart J, 34 (22), 1621-9
    DOI 10.1093/eurheartj/eht013, PubMed 23382466
  380. Agewall S, Tornvall P (2013)
    Thyroid dysfunction in patients with myocardial infarction with normal coronary arteries
    Angiology, 64 (3), 245-6
    DOI 10.1177/0003319712471071, PubMed 23299173
  381. Zannad F, Stough WG, Regnault V, Gheorghiade M, Deliargyris E, Gibson CM, Agewall S, Berkowitz SD, Burton P, Calvo G, Goldstein S, Verheugt FW, Koglin J, O'Connor CM (2013)
    Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges
    Int J Cardiol, 167 (5), 1772-82
    DOI 10.1016/j.ijcard.2012.12.018, PubMed 23298559
  382. Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T (2012)
    Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
    Cardiology, 123 (4), 240-7
    DOI 10.1159/000343622, PubMed 23207160
  383. Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, Lanas A, Agewall S, Nauclér EC, Svedberg LE, Nagy P (2013)
    Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial
    J Cardiovasc Pharmacol, 61 (3), 250-7
    DOI 10.1097/FJC.0b013e31827cb626, PubMed 23188121
  384. Hall TS, Hallén J, Agewall S, Atar D, Jensen T (2012)
    Changes in diagnosing non-ST-segment elevation myocardial infarction after the introduction of a new high-sensitivity cardiac troponin T assay: a single-centre experience
    Clin Lab, 58 (9-10), 1029-36
    PubMed 23163120
  385. Mentz RJ, Hernandez AF, Stebbins A, Ezekowitz JA, Felker GM, Heizer GM, Atar D, Teerlink JR, Califf RM, Massie BM, Hasselblad V, Starling RC, O'Connor CM, Ponikowski P (2012)
    Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF
    Eur J Heart Fail, 15 (4), 456-64
    DOI 10.1093/eurjhf/hfs188, PubMed 23159547
  386. Heldal M, Atar D (2012)
    Pharmacological conversion of recent-onset atrial fibrillation: a systematic review
    Scand Cardiovasc J Suppl, 47 (1), 2-10
    DOI 10.3109/14017431.2012.740572, PubMed 23067130
  387. Namtvedt SK, Hisdal J, Randby A, Agewall S, Stranden E, Somers VK, Røsjø H, Omland T (2012)
    Impaired endothelial function in persons with obstructive sleep apnoea: impact of obesity
    Heart, 99 (1), 30-4
    DOI 10.1136/heartjnl-2012-303009, PubMed 23048165
  388. Angel K, Provan SA, Mowinckel P, Seljeflot I, Kvien TK, Atar D (2012)
    The L-arginine/asymmetric dimethylarginine ratio is improved by anti-tumor necrosis factor-α therapy in inflammatory arthropathies. Associations with aortic stiffness
    Atherosclerosis, 225 (1), 160-5
    DOI 10.1016/j.atherosclerosis.2012.08.033, PubMed 23014354
  389. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction, Authors/Task Force Members Chairpersons, Thygesen K, Alpert JS, White HD, Biomarker Subcommittee, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, ECG Subcommittee, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Imaging Subcommittee, Underwood R, Bax JJ et al. (2012)
    Third universal definition of myocardial infarction
    J Am Coll Cardiol, 60 (16), 1581-98
    DOI 10.1016/j.jacc.2012.08.001, PubMed 22958960
  390. Abdelnoor M, Eritsland J, Brunborg C, Halvorsen S (2012)
    Ethnicity and acute myocardial infarction: risk profile at presentation, access to hospital management, and outcome in Norway
    Vasc Health Risk Manag, 8, 505-15
    DOI 10.2147/VHRM.S33627, PubMed 22956878
  391. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG et al. (2012)
    Third universal definition of myocardial infarction
    Circulation, 126 (16), 2020-35
    DOI 10.1161/CIR.0b013e31826e1058, PubMed 22923432
  392. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines-CPG, Document Reviewers (2012)
    2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association
    Europace, 14 (10), 1385-413
    DOI 10.1093/europace/eus305, PubMed 22923145
  393. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D (2012)
    ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
    Eur Heart J, 33 (20), 2569-619
    DOI 10.1093/eurheartj/ehs215, PubMed 22922416
  394. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA et al. (2012)
    Third universal definition of myocardial infarction
    Eur Heart J, 33 (20), 2551-67
    DOI 10.1093/eurheartj/ehs184, PubMed 22922414
  395. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG) (2012)
    2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association
    Eur Heart J, 33 (21), 2719-47
    DOI 10.1093/eurheartj/ehs253, PubMed 22922413
  396. Halvorsen S (2012)
    STEMI treatment in areas remote from primary PCI centres
    EuroIntervention, 8 Suppl P, P44-50
    DOI 10.4244/EIJV8SPA8, PubMed 22917789
  397. Atar D, Serebruany VL (2012)
    Conclusion
    Adv Cardiol, 47, 165
    DOI 10.1159/000341140, PubMed 22906911
  398. Serebruany VL, Atar D (2012)
    Introduction. Antiplatelet therapy in ACS and A-Fib
    Adv Cardiol, 47, 1-4
    DOI 10.1159/000338206, PubMed 22906898
  399. Prendergast B, Coope LT, Crijns H, Falkenstein E, Fölsch U, Halvorsen S, Janssens S, Jokinen E, Kroemer HK, Lücke A, Murer H, Nagel E, Neyses L, Perk J, Probst-Hensch N, Rietschel ET, Rütten H, Steingen C, Tedgui A, van Gilst W, Eschenhagen T, Kristensen SD (2012)
    The German Centre for Cardiovascular Research
    Eur Heart J, 33 (9), 1033-36,1036a
    PubMed 22893891
  400. Henareh L, Agewall S (2012)
    2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus
    Cardiovasc Diabetol, 11, 93
    DOI 10.1186/1475-2840-11-93, PubMed 22873202
  401. De Blois J, Stranden E, Jogestrand T, Henareh L, Agewall S (2012)
    Echogenicity of the carotid intima-media complex and cardiovascular risk factors
    Clin Physiol Funct Imaging, 32 (5), 400-3
    DOI 10.1111/j.1475-097X.2012.01134.x, PubMed 22856348
  402. Hodt A, Stugaard M, Hisdal J, Stranden E, Atar D, Steine K (2012)
    Regional LV deformation in healthy individuals during isovolumetric contraction and ejection phases assessed by 2D speckle tracking echocardiography
    Clin Physiol Funct Imaging, 32 (5), 372-9
    DOI 10.1111/j.1475-097X.2012.01139.x, PubMed 22856344
  403. Santos RD, Agewall S (2012)
    Non-alcoholic fatty liver disease and cardiovascular disease
    Atherosclerosis, 224 (2), 324-5
    DOI 10.1016/j.atherosclerosis.2012.07.018, PubMed 22840429
  404. Serebruany VL, Atar D (2012)
    Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
    Thromb Haemost, 108 (3), 412-4
    DOI 10.1160/TH12-04-0251, PubMed 22836596
  405. Griffin BA, Agewall S (2012)
    Can increased arterial stiffness in women relative to men be explained by their progressive loss of gluteofemoral fat?
    Atherosclerosis, 224 (2), 320-1
    DOI 10.1016/j.atherosclerosis.2012.05.041, PubMed 22800649
  406. Felker GM, Hasselblad V, Tang WH, Hernandez AF, Armstrong PW, Fonarow GC, Voors AA, Metra M, McMurray JJ, Butler J, Heizer GM, Dickstein K, Massie BM, Atar D, Troughton RW, Anker SD, Califf RM, Starling RC, O'Connor CM (2012)
    Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study
    Eur J Heart Fail, 14 (11), 1257-64
    DOI 10.1093/eurjhf/hfs110, PubMed 22764184
  407. Hjeltnes G, Hollan I, Førre Ø, Wiik A, Lyberg T, Mikkelsen K, Agewall S (2012)
    Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors
    J Rheumatol, 39 (7), 1341-7
    DOI 10.3899/jrheum.111401, PubMed 22660798
  408. Agewall S, DeGroot E, Marcos-Alberca P, Zamorano JL, Barrero AA, Badano LP, Perrone-Filardi P (2012)
    Ultrasound and radiology surrogate endpoints in pharmacological studies
    Atherosclerosis, 224 (1), 12-24
    DOI 10.1016/j.atherosclerosis.2012.03.038, PubMed 22632921
  409. Halvorsen S, Seljeflot I, Weiss T, Bøhmer E, Arnesen H (2012)
    Inflammatory and thrombotic markers in patients with ST-elevation myocardial infarction treated with thrombolysis and early PCI: a NORDISTEMI substudy
    Thromb Res, 130 (3), 495-500
    DOI 10.1016/j.thromres.2012.04.016, PubMed 22607887
  410. Atar D, Ong S, Lansberg PJ (2015)
    Expanding the Evidence Base: Comparing Randomized Controlled Trials and Observational Studies of Statins
    Am J Ther, 22 (5), e141-50
    DOI 10.1097/MJT.0b013e318245ce94, PubMed 22487773
  411. Wisløff T, Selmer RM, Halvorsen S, Fretheim A, Norheim OF, Kristiansen IS (2012)
    Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysis
    BMC Cardiovasc Disord, 12, 26
    DOI 10.1186/1471-2261-12-26, PubMed 22475076
  412. Agewall S (2012)
    [Troponin can be increased in healthy persons following moderate exercise]
    Lakartidningen, 109 (1-2), 18
    PubMed 22468405
  413. Agewall S, Henareh L (2012)
    Low self-estimated quality of life after myocardial infarction and future cardiovascular risk
    Int J Cardiol, 157 (1), 128-9
    DOI 10.1016/j.ijcard.2012.03.044, PubMed 22459393
  414. Hjeltnes G, Hollan I, Førre Ø, Wiik A, Lyberg T, Mikkelsen K, Agewall S (2012)
    Endothelial function improves within 6 weeks of treatment with methotrexate or methotrexate in combination with a TNF-α inhibitor in rheumatoid arthritis patients
    Scand J Rheumatol, 41 (3), 240-2
    DOI 10.3109/03009742.2012.656698, PubMed 22401496
  415. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, European Society of Cardiology (2012)
    [ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)]
    G Ital Cardiol (Rome), 13 (3), 171-228
    DOI 10.1714/1038.11322, PubMed 22395108
  416. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D (2012)
    Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study
    Am J Hypertens, 25 (6), 644-50
    DOI 10.1038/ajh.2012.12, PubMed 22378036
  417. Melki D, Lind S, Agewall S, Jernberg T (2012)
    Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation
    Clin Chim Acta, 413 (9-10), 933-7
    DOI 10.1016/j.cca.2012.02.008, PubMed 22366164
  418. Atar D (2012)
    [How to diagnose a heart attack in 2012?]
    Tidsskr Nor Laegeforen, 132 (3), 265-6
    DOI 10.4045/tidsskr.11.1367, PubMed 22314724
  419. Fagerhol MK, Larsen A, Brun JG, Hammer HB, Angel K, Kvien TK, Kinne I, Madland TM (2012)
    Large molecular size EDTA-resistant complexes containing S100A12, ERAC, in serum during inflammatory conditions
    Scand J Clin Lab Invest, 72 (2), 129-36
    DOI 10.3109/00365513.2011.643819, PubMed 22248048
  420. Wisløff T, Atar D, Sønbø Kristiansen I (2013)
    Cost effectiveness of drug-eluting stents as compared with bare metal stents in patients with coronary artery disease
    Am J Ther, 20 (6), 596-601
    DOI 10.1097/MJT.0b013e3182211a01, PubMed 21822114
  421. Hallén J, Atar D, Serebruany V (2014)
    Effects of FX06 in vitro on platelet, coagulation, and fibrinolytic biomarkers in volunteers and patients with documented coronary artery disease
    Am J Ther, 21 (2), 91-8
    DOI 10.1097/MJT.0b013e3181b0a6ff, PubMed 19770797
  422. Serebruany VL, Atar D (2012)
    Antiplatelet Therapy in ACS and A-Fib Introduction
    Adv.Cardiol., 47, 1-4
  423. Hall TS, Hallen J, Agewall S, Atar D, Jensen T (2012)
    Changes in Diagnosing Non-ST-Segment Elevation Myocardial Infarction after the Introduction of a New High-Sensitivity Cardiac Troponin T Assay: A Single-Centre Experience
    Clin. Lab., 58 (9-10), 1029-1036
    DOI 10.7754/Clin.Lab.2012.111206
  424. Halvorsen S (2015)
    Percutaneous coronary intervention in the patient on oral anticoagulation
    Tidsskr. Nor. Laegeforen., 135 (1), 55
    DOI 10.4045/tidsskr.14.1248
  425. Atar D, Serebruany VL (2012)
    Antiplatelet Therapy in ACS and A-Fib Conclusion
    Adv.Cardiol., 47, 165
  426. Halvorsen S (2016)
    Female hearts A medical textbook about common heart disease
    Tidsskr. Nor. Laegeforen., 136 (4), 333
    DOI 10.4045/tidsskr.15.1299
  427. Blichfeldt-AEro SC, Trondalen G, Halvorsen S (2019)
    Facilitated music listening: Music therapy in an invasive cardiac procedure
    BRIT. J. MUSIC THER., 33 (1), 27-38
    DOI 10.1177/1359457519840131
  428. Rutherford OCW, Konig MSS, Risnes K, Raouf N, Atar D, Ghanima W (2018)
    Serum concentration measurements of DOAK drugs Reply
    Tidsskr. Nor. Laegeforen., 138 (7), 621
  429. Wyller TB, Kjeldsen SE, Halvorsen S, Bath PM, Sandercock P (2020)
    In memoriam Eivind Berge, MD, PhD, 1964-2020: cardiologist, trialist and hypertension/stroke researcher
    J. Hypertens., 38 (6), 1199-1200
    DOI 10.1097/HJH.0000000000002488
  430. Aamodt AH, Bjork MH, Tronvik EA, Buanes EA, Stovner LJ, Atar D (2020)
    Do ACE inhibitors and angiotensin receptor antagonists increase the risk of severe Covid-19?
    Tidsskr. Nor. Laegeforen., 140 (9), 859-860
  431. Pope MK, Ghanima W, Atar D (2020)
    Intensification of antithrombotic therapy for chronic atherosclerosis
    Tidsskr. Nor. Laegeforen., 140 (10), 976-977
  432. Blichfeldt-AEro SC, Halvorsen S, Trondalen G (2021)
    Music therapy in invasive cardiac procedures: Expanded perspective
    BRIT. J. MUSIC THER., 13594575211039090
    DOI 10.1177/13594575211039090

 
Page visits: 1855